Cascadian Therapeutics (ONTY) 10-K 8 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 08, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	Cascadian Therapeutics, Inc.
Entity Central Index Key	1,412,067
Trading Symbol	casc
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		55,317,212
Entity Public Float			$ 118
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 16,777	$ 13,721
Short-term investments	76,500	49,084
Accounts and other receivables	344	238
Prepaid and other current assets	1,218	1,411
Total current assets	94,839	64,454
Long-term investments	7,711
Property and equipment, net	656	1,402
Goodwill	16,659	16,659
Other assets	960	750
Total assets	120,825	83,265
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	2,246	824
Accrued and other liabilities	6,085	3,323
Accrued compensation and related liabilities	3,073	4,274
Current portion of restricted share unit liability	355	352
Total current liabilities	11,759	8,773
Other liabilities		105
Commitments and contingencies
Stockholders’ equity:
Preferred stock. value
Common stock, value	353,852	353,849
Additional paid-in capital	389,637	297,922
Accumulated deficit	(629,268)	(572,334)
Accumulated other comprehensive loss	(5,185)	(5,080)
Total stockholders’ equity	109,036	74,357
Total liabilities and stockholders’ equity	120,825	83,265
Class UA Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ EQUITY
Class UA preferred stock, 12,500 shares authorized, 12,500 shares issued and outstanding	$ 30	$ 30

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2017		Dec. 31, 2016
Preferred stock, shares authorized (in shares)	10,000,000	[1],[2]	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, shares authorized (in shares)	130,000,000		66,666,667
Common stock, shares issued (in shares)	50,598,611		22,562,640
Common stock, shares outstanding (in shares)	50,598,611		22,562,640
Class UA Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	12,500		12,500
Preferred stock, shares issued (in shares)	12,500		12,500
Preferred stock, shares outstanding (in shares)	12,500		12,500
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	2,500		10,000
Preferred stock, shares outstanding (in shares)	2,500		10,000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	5,333		5,333
Preferred stock, shares outstanding (in shares)	5,333		5,333
Series C Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	7,500		7,500
Preferred stock, shares outstanding (in shares)	7,500		7,500
Series D Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	17,250		17,250
Preferred stock, shares outstanding (in shares)	17,250		17,250
Series E Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,818		0
Preferred stock, shares outstanding (in shares)	1,818		0
[1]	The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing
[2]	The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating expenses
Research and development		$ 43,980,000	$ 27,467,000	$ 23,468,000
General and administrative		14,109,000	17,630,000	9,321,000
Intangible asset impairment			19,738,000
Total operating expenses		58,089,000	64,835,000	32,789,000
Loss from operations		(58,089,000)	(64,835,000)	(32,789,000)
Other income
Investment and other income, net		1,155,000	222,000	80,000
Change in fair value of warrant liability				128,000
Total other income, net		1,155,000	222,000	208,000
Loss before income taxes		(56,934,000)	(64,613,000)	(32,581,000)
Income tax benefit			(6,908,000)
Net loss		(56,934,000)	(57,705,000)	(32,581,000)
Net loss attributable to common stockholders		$ (57,916,000)	$ (60,293,000)	$ (32,581,000)
Net loss per share basic and diluted (in dollars per share)	[1]	$ (1.21)	$ (3.13)	$ (2.02)
Shares used to compute basic and diluted net loss per share (1) (in shares)	[1]	47,966,493	19,264,121	16,102,860
Series E Convertible Preferred Stock [Member]
Other income
Deemed dividend related to beneficial conversion feature on convertible preferred stock		$ (982,000)	$ (2,588,000)
[1]	Basic and diluted net loss per share, and shares to used compute basic and diluted net loss per share for the year ended December 31, 2015 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (56,934)	$ (57,705)	$ (32,581)
Other comprehensive income (loss):
Unrealized gains (loss) during the period, net	(105)	(16)	27
Other comprehensive income (loss)	(105)	(16)	27
Comprehensive loss	$ (57,039)	$ (57,721)	$ (32,554)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands		Common Stock [Member]Series B Convertible Preferred Stock [Member]	[1]	Common Stock [Member]Series C Convertible Preferred Stock [Member]		Common Stock [Member]		Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]Series D Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]Series E Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2014						15,266,899	[1]					10,000
Balance at Dec. 31, 2014						$ 353,856						$ 0				$ 224,549	$ (482,048)	$ (5,091)					$ 91,266
Net loss																	(32,581)						(32,581)
Unrealized gain (loss) on available-for-sale securities																		27					27
Stock issued (in shares)		(666,667)		(1,250,000)	[1]	2,449,943	[1]	5,333	7,500
Stock issued				$ (1)		$ 1							$ 1,863			20,557			$ 1,863	$ (1)			20,558
Shares issued (in shares)	[1]					11,255
Issuances under employee stock purchase plan																112							112
Restricted stock units converted (in shares)	[1]					12,231
Restricted stock units converted																278							278
Share-based compensation expense																2,179							$ 2,179
Stock options exercised (in shares)						3,324	[1]																3,324
Stock options exercised																34							$ 34
Balance (in shares) at Dec. 31, 2015						15,826,985	[1]					22,833
Balance at Dec. 31, 2015						$ 353,856						$ 0				249,572	(514,629)	(5,064)					83,735
Net loss																	(57,705)						(57,705)
Unrealized gain (loss) on available-for-sale securities																		(16)					(16)
Stock issued (in shares)						6,708,333	[1]			17,250
Stock issued						$ 4								$ 13,458		29,820					$ 13,458		29,824
Shares issued (in shares)	[1]					19,161
Issuances under employee stock purchase plan																91							91
Restricted stock units converted (in shares)	[1]					8,168
Restricted stock units converted																60							60
Share-based compensation expense																4,685							$ 4,685
Stock options exercised (in shares)																							0
Beneficial conversion feature related to the issuance of preferred stock												(2,588)				2,588
Deemed dividend related to beneficial conversion feature of preferred stock												$ 2,588				(2,588)
Reverse stock split adjustment (in shares)	[1]					(7)
Reverse stock split adjustment						$ (11)										11
Recovery of related party short-swing profit																225							$ 225
Balance (in shares) at Dec. 31, 2016						22,562,640	[1]					40,083
Balance at Dec. 31, 2016						$ 353,849						$ 0				297,922	(572,334)	(5,080)					74,357
Net loss																	(56,934)						(56,934)
Unrealized gain (loss) on available-for-sale securities																		(105)					(105)
Stock issued (in shares)						26,659,300	[1]				1,818
Stock issued						$ 3									$ 5,616	82,353						$ 5,616	82,356
Shares issued (in shares)	[1]					65,437
Issuances under employee stock purchase plan																184							184
Restricted stock units converted (in shares)	[1]					61,210
Restricted stock units converted																236							236
Share-based compensation expense																3,026							$ 3,026
Stock options exercised (in shares)																							0
Beneficial conversion feature related to the issuance of preferred stock												(982)				982
Deemed dividend related to beneficial conversion feature of preferred stock												$ 982				(982)
Recovery of related party short-swing profit																300							$ 300
Conversion of Series A Preferred Shares (in shares)						1,250,024	[1]					(7,500)
Balance (in shares) at Dec. 31, 2017						50,598,611	[1]					34,401
Balance at Dec. 31, 2017						$ 353,852						$ 0				$ 389,637	$ (629,268)	$ (5,185)					$ 109,036
[1]	Common stock shares for the years ended December 31, 2015 and 2014 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Equity (Parentheticals) - Additional Paid-in Capital [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Series B Convertible Preferred Stock [Member]
Stock issued, offering costs			$ 0.1
Series D Convertible Preferred Stock [Member]
Stock issued, offering costs		$ 0.3
Series E Convertible Preferred Stock [Member]
Stock issued, offering costs	$ 0.4
Stock issued, offering costs	$ 5.6	$ 2.4	$ 1.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (56,934,000)	$ (57,705,000)	$ (32,581,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	956,000	642,000	613,000
Amortization of premiums and accretion of discounts on securities	(6,000)	238,000	305,000
Share-based compensation expense	3,345,000	4,609,000	2,748,000
Change in fair value of warrant liability			(128,000)
Intangible assets impairment		19,738,000
Income tax benefit		(6,908,000)
Other	(96,000)	69,000	(7,000)
Net changes in assets and liabilities:
Accounts and other receivables	(106,000)	(38,000)	98,000
Prepaid and other current assets	193,000	7,000	(530,000)
Other long-term assets	(211,000)	(396,000)	(124,000)
Accounts payable	1,422,000	385,000	(250,000)
Accrued and other liabilities	2,762,000	514,000	765,000
Accrued compensation and related liabilities	(1,201,000)	2,752,000	(92,000)
Other long-term liabilities	(105,000)	(638,000)	406,000
Net cash used in operating activities	(49,981,000)	(36,731,000)	(28,777,000)
Cash flows from investing activities
Purchases of investments	(131,752,000)	(92,268,000)	(61,556,000)
Redemption of investments	96,526,000	71,440,000	86,027,000
Purchases of property and equipment	(114,000)	(147,000)	(771,000)
Net cash provided by (used in) investing activities	(35,340,000)	(20,975,000)	23,700,000
Cash flows from financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs	82,540,000	29,914,000	20,669,000
Proceeds from issuance of convertible preferred stock, net of issuance costs	5,616,000	13,458,000	1,863,000
Proceeds from stock options exercised	0	0	34,568
Cash paid upon conversion of restricted share units	(79,000)	(20,000)	(93,000)
Recovery of related party short-swing profit	300,000	225,000
Net cash provided by financing activities	88,377,000	43,577,000	22,473,000
Increase (decrease) in cash and cash equivalents	3,056,000	(14,129,000)	17,396,000
Cash and cash equivalents, beginning of year	13,721,000	27,850,000	10,454,000
Cash and cash equivalents, end of year	16,777,000	13,721,000	27,850,000
Series E Convertible Preferred Stock [Member]
Supplemental disclosures of non-cash investing and financing activities:
Accretion on convertible preferred stock associated with beneficial conversion feature	$ 982,000	$ 2,588,000

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	1. DESCRIPTION OF BUSINESS Cascadian Therapeutics, Inc. (the Company) is a clinical-stage biopharmaceutical company incorporated in the State of Delaware on September 7, 2007 not On January 30, 2018, the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on February 8, 2018, $10

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Basis of presentation These consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (U.S. GAAP) and reflect the following significant accounting policies. Change in Authorized Shares and Reverse Stock Split On November 18, 2016, 200,000,000 66,666,667 33,333,333 66,666,667 June 8, 2017, 66,666,667 130,000,000. On November 29, 2016, one six six ’s common stock were combined into one 1 6 Basis of consolidation The Company ’s consolidated financial statements include the accounts of the company and its wholly-owned subsidiaries, including Cascadian Therapeutics (Australia) Pty Ltd, Protocell Therapeutics Inc., Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira BV and Oncothyreon Luxembourg. All intercompany balances and transactions have been eliminated upon consolidation. Accounting estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make complex and subjective judgments and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. By their nature, these judgments are subject to an inherent degree of uncertainty and as a consequence actual results may Cash and cash equivalents Cash equivalents include short-term, highly liquid investments that are readily convertible to known amounts of cash with original maturities of 90 December 31, 2017, $10.3 $6.5 December 31, 2016, $7.2 $6.6 Investments Investments are classified as available-for-sale securities and are carried at fair value with unrealized temporary holding gains and losses excluded from net income or loss and reported in other comprehensive income or loss and as a net amount in accumulated other comprehensive income or loss until realized. Available-for-sale securities are written down to fair value through income whenever it is necessary to reflect other-than-temporary impairments. The Company determined that the unrealized losses on its marketable securities as of December 31, 2017 not one 12 not may third third third Amortized Cost Gross Unrealized Gross Unrealized Fair Value (In thousands) As of December 31, 2017: Cash $ 10,300 $ — $ — $ 10,300 Money market funds 6,477 — — 6,477 Debt securities of U.S. government agencies 57,851 — (98 ) 57,753 Corporate bonds 26,479 — (21 ) 26,458 Total $ 101,107 $ — $ (119 ) $ 100,988 As of December 31, 2016: Cash $ 7,162 $ — $ — $ 7,162 Money market funds 6,559 — — 6,559 Debt securities of U.S. government agencies 38,387 1 (10 ) 38,378 Corporate bonds 10,711 — (5 ) 10,706 Total $ 62,819 $ 1 $ (15 ) $ 62,805 The following table summarizes the aggregate related fair value of investments with unrealized losses by investment category: As of December 31, 2017 As of December 31, 2016 Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses (In thousands) Debt securities of U.S. government agencies $ 55,276 $ (98 ) $ 31,990 $ (10 ) Corporate bonds 26,458 (21 ) 8,955 (5 ) Total $ 81,734 $ (119 ) $ 40,945 $ (15 ) The following table summarizes the Company ’s available for sale securities by contractual maturity: As of December 31, 2017 As of December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value (In thousands) Less than one year $ 83,080 $ 82,977 $ 55,657 $ 55,643 Greater than one year but less than five years 7,727 7,711 — — Total $ 90,807 $ 90,688 $ 55,657 $ 55,643 Warrants Warrants issued in connection with the Company ’s September 2010 September 2010 October 12, 2015. No December 31, 2017 2016. Accounts and other receivables Accounts and other receivables are reviewed whenever circumstances indicate that the carrying amount of the receivable may not As of December 31, 2017, not Property and equipment, depreciation and amortization Property and equipment are recorded at cost and depreciated over their estimated useful lives on a straight-line basis, as follows: Scientific and office equipment 5 years Computer software and equipment 3 years Leasehold improvements and leased equipment Shorter of useful life or the term of the lease Long-lived assets Long-lived assets, such as property and equipment , are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third $0.1 December 31, 2017. No December 31, 2016 2015. Indefinite-lived i ntangible a ssets — IPR&D Intangible assets related to In Process Research & Development (IPR&D) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon completion of the project, the Company will make a separate determination of useful life of the IPR&D and the related amortization will be recorded as an expense over the estimated useful life. If the IPR&D is abandoned, the carrying value of the asset will be expensed. During the period the assets are considered indefinite-lived, they will not October 1 may Goodwill Goodwill is not October 1 may No Other liabilities Other liabilities include the long-term portion of accrued milestone payments and deferred rent. Certain milestone payments under our previous agreement with STC.UNM are accrued on a straight-line basis from initiation of the license agreement to the milestone payment date. Also included in this line item is the long-term portion of deferred rent. Rent expense is recognized on a straight-line basis over the term of the lease. Lease incentives, including rent holidays provided by lessors, and rent escalation provisions are accounted for as deferred rent. Revenue recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable, and collection is reasonably assured. Research and development costs Research and development expenses include personnel and facility related expenses, which includes depreciation and amortization, outside contract services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. In instances where the Company enters into agreements with third may may The Company ’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with numerous clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third may Income or loss per share Basic net loss per share is calculated by dividing net loss attributable to common stockholders, which may 2010 December 31, 2017, 2016 2015, 1 6 6 Income taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future income tax consequences attributable to differences between the carrying amounts and tax bases of assets and liabilities and losses carried forward and tax credits. Deferred tax assets and liabilities are measured using enacted tax rates and laws applicable to the years in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to the extent that it is more likely than not not The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company does not twelve none, Accumulated other comprehensive income (loss) Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company ’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. There were no years ended December 31, 2017, 2016 2015. December 31, 2017, 2016 2015: Net U nrealized G ains/(losses) on S ale Foreign Currency Adjustment Accumulated Other (In thousands) Balance at December 31, 2014 $ (25 ) $ (5,066 ) $ (5,091 ) Other comprehensive income 27 — 27 Balance at December 31, 2015 $ 2 $ (5,066 ) $ (5,064 ) Other comprehensive loss (16 ) — (16 ) Balance at December 31, 2016 $ (14 ) $ (5,066 ) $ (5,080 ) O ther comprehensive loss (105 ) — (105 ) Balance at December 31, 2017 $ (119 ) $ (5,066 ) $ (5,185 ) Share-based compensation The Company recognizes in the statements of operations the estimated grant date fair value of share-based compensation awards granted to employees over the requisite service period. Share-based compensation expense in the consolidated statements of operations is recorded on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period, with the offset to additional paid-in capital. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted to employees. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. On June 23, 2016, ’s stockholders approved a new 2016 2016 2016 June 8, 2017, 2016 2016 1,200,905 7,900,905 For non-employee directors, the Company sponsors a RSU Plan that was established in 2005. October 2011, 25% ’ U.S. federal income tax obligation with respect to the vested RSUs. This amendment resulted in the RSUs being classified as a liability. The outstanding RSU awards are required to be re-measured at each reporting date until settlement of the award, and changes in valuation are recorded as compensation expense for the period. To the extent that the liability recorded in the balance sheet is less than the original award value, the difference is recognized in equity. The Company uses the closing share price of its shares on the Nasdaq Global Market at the reporting or settlement date to determine the fair value of RSUs. In June 2014, 83,333 June 23, 2016, 2016 2016 The Company maintains an ESPP under which a total of 150,000 For additional information regarding share-based compensation, see “Note 7 Business Combinations In a business combination, the Company determines if the acquired property and activities meet the definition of a business under current accounting guidance. If the combination meets the definition of a business, the Company measures the significance of the combination to determine the required reporting and disclosure requirements for the transaction. Business combinations are required to be accounted for under the acquisition method which requires that identifiable assets acquired, liabilities assumed and any non-controlling interest in the acquiree be recognized and measured as of the acquisition date at fair value. In addition, all consideration transferred must be measured at its acquisition-date fair value. When necessary, the Company uses a third not Segment information The Company operates in a single — research and development of therapeutic products for the treatment of cancer. Recent accounting pronouncements In January 2017, 2017 04, Intangibles – Goodwill and Other (Topic 350 2 December 15, 2019. January 1, 2017. may In August 2016, 2016 15, 230 a consensus of the FASB’s Emerging Issues Task Force. The standard is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard addresses the classification of cash flows related to ( 1 2 zero 3 4 5 6 7 December 15, 2017, January 1, 2018. not In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, December 15, 2016, January 1, 2017. not In February 2016, 2016 02, 842 December 15, 2018, may In January 2016, 2016 01, – Overall (Subtopic 825 10 not not not 2016 01 December 15, 2017, not January 1, 2018. not In August 2015, 2015 14, 606 —Deferral of the Effective Date, which defers by one 2014 09, December 15, 2017, December 15, 2016, January 1, 2018. not not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. FAIR VALUE MEASUREMENTS The Company measures certain financial assets and liabilities at fair value in accordance with a hierarchy which requires an entity to maximize the use of observable inputs which reflect market data obtained from independent sources and minimize the use of unobservable inputs. There are three may • Level 1 • Level 2 1 not • Level 3 no The Company ’s financial assets and liabilities measured at fair value on a recurring basis consisted of the following as of December 31, 2017 2016: December 31, 2017 December 31, 201 6 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In thousands) Financial Assets: Money market funds $ 6,477 $ — $ — $ 6,477 $ 6,559 $ — $ — $ 6,559 Debt securities of U.S. government agencies — 57,753 — 57,753 — 38,378 — 38,378 Corporate bonds — 26,458 — 26,458 — 10,706 — 10,706 $ 6,477 $ 84,211 $ — $ 90,688 $ 6,559 $ 49,084 $ — $ 55,643 Financial Liability: Restricted Share Units $ 355 $ — $ — $ 355 $ 352 $ — $ — $ 352 If quoted market prices in active markets for identical assets are not third 2 There were no 1 2 201 6.

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. PROPERTY AND EQUIPMENT The table below outlines the cost, accumulated depreciation and amortization and net carrying value of the Company ’s property and equipment for the years ended December 31, 2017 2016: 201 7 Cost Accumulated Depreciation Net Carrying (In thousands) Scientific equipment $ 1,192 $ (939 ) $ 253 Leasehold improvements 1,868 (1,829 ) 39 Computer software and equipment 423 (325 ) 98 Office equipment 364 (98 ) 266 $ 3,847 $ (3,191 ) $ 656 201 6 Cost Accumulated Depreciation Net Carrying (In thousands) Scientific equipment $ 3,077 $ (2,241 ) $ 836 Leasehold improvements 1,627 (1,269 ) 358 Computer software and equipment 390 (315 ) 75 Office equipment 170 (37 ) 133 $ 5,264 $ (3,862 ) $ 1,402 Depreciation and leasehold improvement amortization expense was $1.0 $0.6 $0.6 December 31, 2017, 2016 2015, December 31, 2017 $0.3 May 2008

Note 5 - Intangible Asset Impai

Note 5 - Intangible Asset Impairment	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Asset Impairment Charges [Text Block]	5 . INTANGIBLE ASSET IMPAIRMENT On May 5, 2016, ’s intent to no 2014 $19.7 December 31, 2016. $6.9 December 31, 2016. 10 not

Note 6 - Share Capital

Note 6 - Share Capital	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6 . SHARE CAPITAL The Company has the authority to issue a total of 140,012,500 three ● 130,000,000 shares of Common Stock, $0.0001 ● 10,000,000 ( 1 $0.0001 ● 12,500 no ( 1 The Preferred Stock may one The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing Class UA preferred stock As of December 31, 2017 2016, 12,500 Voting. Each share of Class UA preferred stock will not Conversion. The Class UA preferred stock is not Dividends. The holders of the shares of Class UA preferred stock will not Liquidation preference. In the event of any liquidation, dissolution or winding up of the Company, the holders of the Class UA preferred stock will be entitled to receive, in preference to the holders of the Company’s common stock, an amount equal to the lesser of ( 1 20% 20% 2 $100 Holders of Class UA preferred stock are entitled to mandatory redemption of their shares if the Company realizes “net profits” in any year. For this purpose, “net profits … means the after-tax profits determined in accordance with generally accepted accounting principles, where relevant, consistently applied.” The Company has taken the position that this applies to Canadian GAAP and, accordingly, there have been no Redemption. The Company may, $100 $100 20% $100. The difference between the redemption value and the book value of the Class UA preferred stock will be recorded at the time that the fair value of the shares increases to redemption value based on the Company becoming profitable as measured using Canadian GAAP. Preferred stock As of December 31, 2017 2016, 10,000,000 $0.0001 December 31, 2017, 2,500 5,333 7,500 17,250 1,818 December 31, 2016, 10,000 5,333 7,500 17,250 may one Series A Convertible Preferred Stock As of December 31, 2017 2016, 2,500 10,000 July 2017, 7,500 1,250,024 On September 22, 2014, 10,000 ’s Series A convertible preferred stock, the Company designated 10,000 166.67 4.99% $0.0001 no not ● senior to all common stock; ● senior to any class or series of capital stock created specifically ranking by its terms junior to the Series A convertible preferred stock; ● on parity with the Company’s Series B convertible preferred stock, Series C convertible preferred stock and any class or series of capital stock created specifically ranking by its terms on parity with the Series A convertible preferred stock; and ● junior to the Company ’s Class UA preferred stock and any class or series of capital stock created specifically ranking by its terms senior to the Series A convertible preferred stock; in each case, as to distribution of assets upon the Company ’s liquidation, dissolution or winding up whether voluntarily or involuntarily. Series B Convertible Preferred Stock As of December 31, 2017 2016, 5,333 On February 11, 2015, in connection with the public offering of 1,333 5,333 166.67 4.99% $0.0001 no not ● senior to all common stock; ● senior to any class or series of capital stock created specifically ranking by its terms junior to the Series B convertible preferred stock; ● on parity with the Company ’s Series A convertible preferred stock, Series C convertible preferred stock and any class or series of capital stock created specifically ranking by its terms on parity with the Series B convertible preferred stock; and ● junior to the Company ’s Class UA preferred stock and any class or series of capital stock created specifically ranking by its terms senior to the Series B convertible preferred stock; in each case, as to distributions of assets upon the Company ’s liquidation, dissolution or winding up whether voluntarily or involuntarily. Series C Convertible Preferred Stock As of December 31, 2017 2016, 7,500 On May 14, 2015, 7,500 1,245,022 7,500 166.67 9.99% $0.0001 no not : • senior to all common stock; • senior to any class or series of capital stock hereafter created specifically ranking by its terms junior to the Series C Convertible Preferred Stock; • on parity with the Company ’s Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series C Convertible Preferred Stock; and • junior to the Company ’s Class UA Preferred Stock and any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series C Convertible Preferred Stock; in each case, as to distributions of assets upon the Company ’s liquidation, dissolution or winding up whether voluntarily or involuntarily. Series D Convertible Preferred Stock As of December 31, 2017 2016, 17,250 O n June 28, 2016, 17,250 $800.00 $13.8 17,250 Each share of Series D Convertible Preferred Stock is convertible into 166.67 19.99% may 19.99% 61 $0.0001 no not ● senior to all common stock; ● senior to any class or series of capital stock created that specifically ranks by its terms junior to the Series D convertible preferred stock; ● on parity with the Company ’s Series A convertible preferred stock, Series B Convertible Preferred Stock and Series C convertible preferred stock, and any class or series of capital stock created that specifically ranks by its terms on parity with the Series D convertible preferred stock; and ● junior to the Company ’s Class UA preferred stock and any class or series of capital stock created that specifically ranks by its terms senior to the Series D convertible preferred stock; in each case, as to distributions of assets upon the Company ’s liquidation, dissolution or winding up, whether voluntarily or involuntarily. Beneficial Conversion Feature A beneficial conversion feature exists when the effective conversion price of a convertible security is less than the market price per share on the commitment date, creating a discount. The value of the discount is determined by the difference between the market price and the conversion price multiplied by the potential conversion shares purchased. The discount is recognized as a non-cash deemed dividend from the date of issuance to the earliest conversion date. The Company recognized a beneficial conversion feature in the amount of $2.6 $2.6 as recorded in additional paid-in capital and as a deemed dividend on the Series D convertible preferred stock, and was used in determining the net loss applicable to common stockholders in the consolidated statement of operations for the year ended December 31, 2016. Series E Convertible Preferred Stock As of December 31, 2017 2016, 1,818 zero O n January 27, 2017, 1,818 $3,300 $6.0 1,818 Each share of Series E Convertible Preferred Stock is convertible into 1,000 ’s Common Stock at any time at the holder’s option. The holder, however, will be prohibited from converting Series E Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 19.99% may 19.99% 61 $0.0001 no not ● senior to all common stock; ● senior to any class or series of capital stock created that specifically ranks by its terms junior to the Series E convertible preferred stock; ● on parity with the Company ’s Series A convertible preferred stock, Series B Convertible Preferred Stock, Series C convertible preferred stock and Series D convertible preferred stock, and any class or series of capital stock created that specifically ranks by its terms on parity with the Series E convertible preferred stock; and ● junior to the Company ’s Class UA preferred stock and any class or series of capital stock created that specifically ranks by its terms senior to the Series E convertible preferred stock; in each case, as to distributions of assets upon the Company ’s liquidation, dissolution or winding up, whether voluntarily or involuntarily. Beneficial Conversion Feature A beneficial conversion feature exists when the effective conversion price of a convertible security is less than the market price per share on the commitment date, creating a discount. The value of the discount is determined by the difference between the market price and the conversion price multiplied by the potential conversion shares purchased. The discount is recognized as a non-cash deemed dividend from the date of issuance to the earliest conversion date. The Company recognized a beneficial conversion feature as a non-cash dividend in the amount of $1.0 $1.0 year ended December 31, 2017. Common stock On June 8, 2017, 66,666,667 130,000,000. On November 18, 2016, ’s stockholders approved a 1 6 200,000,000 66,666,667 33,333,333 66,666,667 November 29, 2016. As of December 31, 2017 2016, 130,000,000 66,666,667 $0.0001 one no Amounts pertaining to issuances of common stock are classified as common stock on the consolidated balance sheet, approximately $5,060 $2,256 December 31, 2017 2016, Warrants In connection with certain equity and debt financings, the Company issued warrants to purchase shares of its common stock. In February 2011, 8,116 In June 2013, 833,333 A summary of outstanding warrants as of December 31, 2017 2016 201 7 201 6 Shares Underlying Shares Underlying Balance, beginning of year 841,449 841,449 Balance, end of year 841,449 841,449 The following table summarizes information regarding warrants outstanding at December 31, 2017: Exercise Prices Shares Underlying Expiry Date $ 18.48 8,116 February 8, 2018 $ 30.00 833,333 December 5, 2018 841,449 Years Ended December 31, 201 7 201 6 Shares underlying warrants outstanding classified as equity 841,449 841,449 Equity Financings On January 27, 2017, 26,659,300 $3.30 $88.0 3,477,300 1,818 $3,300 $6.0 1,000 19.99% $94.0 $6.0 $88.0 On June 28, 2016, the Company closed an underwritten public offering of 6,708,333 $4.80 $32.2 875,000 17,250 $800.00 $13.8 1,000 19.99% $46.0 $2.7 $43.3 On February 6, 2015, two February 11, 2015, 2,250,000 $9.00 $20.3 1,333 $1,500 $2.0 166.67 4.99% 30 337,500 February 18, 2015, 199,943 $9.00 $1.7 $24.0 $1.6 $22.4 “At-the-Market” Equity Offering Program On June 2, 2016, $0.0001 $50,000,000, January 23, 2017. No Net loss per share Basic net loss per share is calculated by dividing net loss attributable to common stockholders, which may ’s common stock include stock options, restricted share units, warrants, Series A, B, C, D and E convertible preferred stock and shares granted under the 2010 December 31, 2017, 2016 2015 The following table is a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations for the years ended December 31, 2017, 2016 2015. Years Ended December 31, 201 7 201 6 201 5 (in thousands, except share and per share amounts) Numerator: Net loss attributable to common stockholders used to compute net loss per share Basic $ (57,916 ) $ (60,293 ) $ (32,581 ) Diluted $ (57,916 ) $ (60,293 ) $ (32,581 ) Denominator: Weighted average shares outstanding used to compute net loss per share: Basic 47,966,493 19,264,121 16,102,860 Diluted 47,966,493 19,264,121 16,102,860 Net loss per share —basic and diluted $ (1.21 ) $ (3.13 ) $ (2.02 ) The following table presents the number of shares that were excluded from the number of shares used to calculate diluted net loss per share . The share data for the years ended December 31, 2017, 2016 2015 1 6 Years Ended December 31, 201 7 201 6 201 5 Director and employee stock options 3,170,542 1,866,711 1,225,194 Warrants 841,449 841,449 841,449 Convertible preferred stock (as converted to common stock): Series A 416,673 1,666,697 1,666,697 Series B 888,851 888,851 888,851 Series C 1,250,022 1,250,022 1,250,022 Series D 2,875,055 2,875,055 — Series E 1,818,000 — — Employee restricted share units 327,820 — — Non-employee director restricted share units 95,999 81,619 38,157 Employee stock purchase plan 4,237 1,830 449

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7 . SHARE-BASED COMPENSATION The Company uses the Black-Scholes option pricing model to value the options at each grant date, using the following weighted average assumptions: 2017 2016 2015 Expected dividend rate 0.00 % 0.00 % 0.00 % Expected volatility 76.47 % 74.63 % 72.15 % Risk-free interest rate 1.94 % 1.46 % 1.63 % Expected life of options in years 5.69 6.22 6.00 The expected life represents the period that the Company ’s stock options are expected to be outstanding and is based on historical data. The expected volatility is based on the historical volatility of the Company’s common stock for a period equal to the stock option’s expected life. The risk-free interest rate is based on the yield at the time of grant of a U.S. Treasury security with an expected term equivalent to the expected term of the option. The Company does not may not The Company recognizes share-based compensation expense net of estimated forfeitures. The forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company ’s estimated forfeiture rate at the time of grant is based on its historical experience. Share-based compensation expense under the 2016 2016 was $3.2 4.8 $2.1 December 31, 2017, 2016 2015, December 31, 2016 first 2016. not $5.3 December 31, 2017, 33 A summary of option activity under the 2016 December 31, 2017, December 31, 2017 Options Stock Options Weighted Average Weighted Average Aggregate Intrinsic Value In US dollars ($US): Outstanding at January 1, 2017 1,866,711 $ 13.36 Granted 1,508,623 4.27 Exercised — — Forfeited (100,680 ) 13.08 Expired (104,112 ) 23.16 Outstanding at December 31, 2017 3,170,542 $ 8.73 7.57 $ 1,128 Vested or expected to vest at December 31, 2017 2,940,709 $ 9.02 7.45 $ 976 Vested and exercisable at December 31, 2017 1,096,633 $ 14.57 5.25 $ — The weighted average grant-date fair values of options granted were $ 2.81, $4.53 $13.40 December 31, 2017, 2016 2015, The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company ’s common stock for all options that were in-the-money at December 31, 2017. December 31, 2017, 2016 2015 $10.9 $10.6 $8.0 No December 31, 2017 2016. 3,324 December 31, 2015. December 31, 2017 2016 zero December 31, 2015 $34,568 $39,859, December 31, 2017, no $3.70 2016 On June 23, 2016, ’s stockholders approved the 2016 2016 2016 1,200,905 2016 1,050,000 2016 82,884 68,021 2016 2016 June 8, 2017, 2016 2016 1,200,905 7,900,905 December 31, 2017, 5,723,523 2016 All grants under the 2016 may ten ’s minimum required withholding tax on the value of the vested RSUs. The Company measures and recognizes compensation expense for equity-classified restricted stock units (RSUs), and stock options granted to its employees based on the fair value of the awards on the date of grant. The fair value of each RSU was determined to be the closing trading price of the Company’s common shares on the date of grant as quoted in Nasdaq Global Market. The fair value of stock options is estimated at the date of grant using the Black-Scholes option pricing model. Share-based compensation expense for equity-classified RSUs, and stock options is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. RSU grants made to its non-employee directors are classified as liabilities. Share-based compensation expense for liability-classified RSUs are re-measured at each reporting date until settlement of the award. A summary of the RSU activity under the 2016 December 31, 2017, Restricted Share Units to Employees Restricted Share Weighted Average Non-vested at January 1, 2017 — $ — Granted 335,920 4.24 Forfeited (8,100 ) 4.55 Non-vested at December 31, 2017 327,820 $ 3.70 Expected to vest at December 31, 2017 327,820 $ 3.70 Restricted Share Units to Non-Employee Directors Restricted Share Weighted Average Non-vested at January 1, 2017 54,348 $ 4.31 Granted 95,999 3.65 Converted (54,348 ) 3.86 Non-vested at December 31, 2017 95,999 $ 3.70 Expected to vest at December 31, 2017 95,999 $ 3.70 Under the 2016 he Company granted 95,999 $350,000 54,348 $300,000 December 31, 2017 2016, 54,348 December 31, 2017. 54,348 $3.86 54,348 December 31, 2017. 13,590 54,348 December 31, 2017. $52,412, December 31, 2017. December 31, 2017, no Share option plan The Company sponsor ed an Option Plan under which a maximum fixed reloading percentage of 10% may April 1, 2008, April 1, 2008, December 31, 2016, 313,040 No December 31, 2016. June 23, 2016, 2016 January 2010 one four eight January 2010 25% first 36 first eight 2016 June 23, 2016, 2016 no Inducement Grant On April 4, 2016, of 474,810 25% first 36 first ten No December 31, 2017. Restricted share unit plan The RSU Plan was established in 2005 June 23, 2016, 2016 The RSU Plan provided for grants to be made from time to time by the board of directors or a committee thereof. RSU grants to non-employee directors are classified as liabilities. The fair value of each RSU was determined to be the closing trading price of the Company ’s common shares on the date of grant as quoted in Nasdaq Global Market. Each RSU granted was made in accordance with the RSU Plan and terms specific to that grant. Outstanding RSUs under the RSU Plan have a vesting term of one two 75% 0.75 25% 0.25 Upon vesting, RSUs of 27,271,10,893 16,308 $3.87, $18.36 $22.75 27,271, 10,893 16,308 December 31, 2017, 2016 2015, October 2011 6,819 27,271 December 31, 2017, 2,723 10,893 December 31, 2016 4,078 16,308 December 31, 2015. $26,395, $20,098 $92,759, December 31, 2017, 2016 2015, Upon the adoption of the 2016 June 23, 2016, 2016 A summary of the RSU activity under the RSU Plan as of December 31, 2017, December 31, 2017 Restricted Share Units Restricted Share Weighted Average Non-vested at January 1, 2017 27,271 $ 4.31 Converted (27,271 ) 3.87 Non-vested at December 31, 2017 — $ — Expected to vest at December 31, 2017 — $ — As of December 31, 2017, no $11,980 $0.3 December 31, 2017 2016, $0.6 December 31, 2015. Employee Stock Purchase Plan (ESPP) The Company adopted an ESPP on June 3, 2010, 150,000 may six 18 may not 15% may not $25,000 not 85% 85% may 15,000 Fair value of shares purchases under the Company ’s ESPP was estimated at subscription dates using a Black-Scholes valuation model, which requires the input of highly subjective assumptions including expected stock price volatility and expected term. The expected volatility is based on the historical volatility of the Company’s common stock for a period equal to the ESPP’s expected term, which is determined by length of time between the subscription date and the purchase date. The risk-free interest rate is based on the yield at the time of grant of a U.S. Treasury security with an equivalent expected term of the ESPP. The Company does not For the year ended December 31, 2017, 2016 2015, $0.2 $0.1 $0.1 December 31, 2017, 4,237 $0.1 1.04 December 31, 2017, 2016 2015: Shares Issued for the Year s Ended December 31 , Purchase Prices 2017 2016 2015 $ 2.81 65,437 — — $ 4.45 — 10,900 — $ 5.10 — 8,261 — $ 8.94 — — 4,698 $ 9.72 — — 1,899 $ 11.10 — — 4,656 Total 65,437 19,161 11,253

Note 8 - Collaborative and Lice

Note 8 - Collaborative and License Agreements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	8 . COLLABORATIVE AND LICENSE AGREEMENTS Array BioPharma, Inc. On December 11, 2014, 380 HER2 Under the terms of the License Agreement, the Company paid Array an upfront fee of $20 third Array is also entitled to receive up to a low double-digit royalty based on net sales of tucatinib by the Company and a single-digit royalty based on net sales of tucatinib by the Company’s sublicensees. The term of the license agreement expires on a country-by-country basis upon the later of the expiration of the last valid claim covering tucatinib within that country or 10 first The License Agreement will expire on a country-by-country basis 10 first may 180 STC.UNM Effective June 30, 2014, Biosciences, Inc, (Alpine) entered into an exclusive license agreement with STC.UNM, by assignment from The Regents of the University of New Mexico, to license the rights to use certain technology relating to protocells, a mesoporous silica nanoparticle delivery platform. The Company subsequently acquired Alpine in August 2014. On May 5, 2016, $325,000. ’s intent to no 2014 $19.7 December 31, 2016. $6.9 December 31, 2016, $1.5 December 31, 2016. not 5 10 Sentinel Oncology Ltd. In April 2014, Chk1 has made payments to Sentinel to support their chemistry research. The Company is responsible for preclinical and clinical development, manufacturing and commercialization of any resulting compounds. Sentinel is eligible to receive success-based development and commercial milestone payments up to approximately $90 $1.0 first

Note 9 - Net Investment and Oth

Note 9 - Net Investment and Other Income (Expense)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	9. NET INVESTMENT AND OTHER INCOME (EXPENSE) Net investment and other income (expense) include the following components for the periods indicated: Years Ended December 31, 201 7 201 6 201 5 (In thousands) Investment income, net $ 1,065 $ 240 $ 73 Net foreign exchange gain (loss) (5 ) 1 (5 ) Gain (loss) on sale of equipment 170 (69 ) 7 Gain on sale of investment — — — Impairment expense (75 ) — — Other income — 50 5 Total investment and other income, net $ 1,155 $ 222 $ 80

Note 10 - Income Tax

Note 10 - Income Tax	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10 . INCOME TAX The provision (benefit) for income taxes consists of the following: 2017 2016 2015 (In thousands) Current income tax expense (benefit) $ — $ — $ — Deferred income tax expense (benefit) — (6,908 ) — Total income tax expense (benefit) $ — $ (6,908 ) $ — The Company recorded an income tax benefit of $6.9 2016 Tax Reform The Tax Cuts and Jobs Act (“U.S. Tax Act”) was enacted on December 22, 2017. December 31, 2017, not In all cases, the Company will continue to make and refine its calculations as additional analysis is completed. In addition, its estimates may The U.S. Tax Act reduces the U.S. federal corporate tax rate from 35% 21% 2018. $50.1 no Starting in 2018, may “GILTI”) which is a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations as well as the new base erosion anti-abuse tax (“BEAT”) under the TCJA. GILTI will be effectively taxed at a tax rate of 10.5%. 1 2 118. not The provision for income taxes was different from the expected statutory federal income tax rate as follows: 2017 2016 201 5 Tax benefit at statutory rate 35.0 % 35.0 % 35.0 % Change in fair value of warrant liability 0.0 0.0 0.1 Stock based compensation (1.6 ) (0.9 ) 0.8 Other 0.0 0.4 0.4 Tax law changes (88.1 ) 0.0 0.0 Change in valuation allowance 54.7 (23.7 ) (40.0 ) Net operating loss expiration and true ups 0.0 0.0 3.7 Income tax benefit (provision) 0.0 % 10.8 % 0.0 % The Company ’s net deferred tax assets and deferred tax liabilities were recorded in other assets and accrued and other liabilities, respectively on the Consolidated Balance Sheets and consist of the following as of December 31, 2017 2016: 2017 201 6 (In thousands) Deferred tax assets Accrued expenses and other $ 623 $ 1,510 Tax benefits from losses carried forward and tax credits 126,552 147,001 Stock based compensation 2,547 4,119 Intangible assets 5,312 9,776 Other 242 207 Total deferred tax assets $ 135,276 $ 162,613 Valuation allowance (135,180 ) (162,414 ) Net deferred tax assets 96 199 Deferred tax liabilities Prepaid expenses 96 199 Intangible asset — — Total deferred tax liabilities 96 199 Net deferred tax liability $ — $ — Based on the available evidence, the Company has recorded a full valuation allowance against its net deferred income tax assets as it is more likely than not not $27.2 $17.0 December 31, 2017 December 31, 2016, The Company has recorded the following reserve for uncertain tax positions as of December 31, 2017, 2016 2015: 201 7 2016 2015 (In thousands) Balance at January 1 $ 662 $ 662 $ 545 Increase related to prior year tax positions 117 Decrease related to current year tax positions — — — Lapses of statute of limitations — — — Balance at December 31 $ 662 $ 662 $ 662 None not not 12 United States The Company has accumulated net operating losses of $317.1 $260.0 December 31, 2017 2016, 382 may not 2018 2037. $0.7 2018 2029, not Canada The Company has unclaimed Canada federal investment tax credits of $16.2 $15.2 December 31, 2017 2016, 2018 2028. $109.1 $102.1 $47.8 $44.7 December 31, 2017 2016, may may $150.2 $140.6 $150.3 $140.7 December 31, 2017 2016, $5.2 $4.8 December 31, 2017 2016 $3.4 $3.1 December 31, 2017 2016 2026 2036. 2008. 2008 may Australia The Company formed an Australian entity in late 2017. $0.2 December 31, 2017. Other The Company files federal and foreign income tax returns in the United States and abroad. For U.S. federal income tax purposes, the statute of limitations is open for 1998 ASU 2016 09 In 2017, 2016 09 $5 ,000

Note 11 - Contingencies, Commit

Note 11 - Contingencies, Commitments, and Guarantees	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments Contingencies and Guarantees [Text Block]	1 1 . CONTINGENCIES, COMMITMENTS, AND GUARANTEES On January 9, 2016, January 11, 2016 January 10, 2017 no January 2017, $2.5 $0.1 $2.3 December 31, 2017 2016, December 31, 2017, no Royalties Pursuant to various license agreements, the Company may December 31, 2017, no no no no not Employee benefit plan Under a defined contribution plan available to permanent employees, the Company is committed to matching employee contributions up to limits set by the terms of the plan, as well as limits set by U.S. tax authorities. The Company’s matching contributions to the plan totaled $0.3 $0.2 $0.2 December 31, 2017, 2016 2015, no December 31, 2017. Lease obligations — operating leases The Company is committed to annual minimum payments under operating lease agreements for its office and laboratory space and equipment) as follows (in thousands): Year Ending December 31, 201 8 $ 849 2019 1,368 2020 1,410 2021 1,454 2022 499 Thereafter — Total $ 5,580 Rental expense for operating leases in the amount of $0.5 December 31, 2017, 2016 2015. On December 4, 2017, the Company entered into a lease for a new office location in Seattle, Washington totaling approximately 44,050 January 1, 2018and April 30, 2022. $110,125 2018, $124,808 2022. In May 2008, the Company entered into a lease for a facility in Seattle, Washington totaling approximately 17,000 November 2016 2,600 $47,715, $57,910 2018. December 4, 2017, May 9, 2008 January 2018, The Company has also entered into operating lease obligations through November 2019 Guarantees In the normal course of operations, the Company indemnifies counterparties in transactions such as purchase and sale contracts for assets or shares, manufacturing and other service agreements, license agreements, director/officer contracts and leasing transactions. These indemnification agreements may third ’s breach of contract or negligence, environmental liabilities, or as a result of litigation claims or statutory sanctions that may not no

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	1 2 . RELATED PARTY TRANSACTIONS Certain of the Company ’s affiliates participated in the Company’s recent public underwritten offerings. In January 2017, 26,659,300 $3.30 $88.0 1,818 $3,300 $6.0 5% 1,818 $6.0 June 2016, 6,708,333 $4.80 $32.2 17,250 $800.00 $13.8 5% 17,250 $13.8 In January 2016, Lampert is an affiliate of BVF. On January 17, 2017, In December 2017, he Company entered into an agreement with CTI BioPharma, Corp (CTI) to sublease property located at 3101 5% 10% January 2017, may Recovery of Stockholder Short-Swing Profit In August 2016 November 2017, $0.2 $0.3 16 1934. December 31, 2016 2017,

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	1 3 . SUBSEQUENT EVENTS On January 31, 2018, the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire the Company. Under the terms of the agreement, Seattle Genetics will pay $10.00 $614 Under the terms of the definitive merger agreement, on February 8, 2018, February 8, 2018 $10 1976. not $10 first 2018.

Note 14 - Condensed Quarterly F

Note 14 - Condensed Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	1 4 . CONDENSED QUARTERLY FINANCIAL DATA (unaudited) The following table contains selected unaudited statement of operations information for each quarter of 201 7 2016. not Quarterly Financial Data: Three Months Ended, March 31 June 30 September 30 December 31 (In thousands, except per share data) 201 7 Operating expenses ( 1 ) $ 11,562 $ 15,021 $ 14,358 $ 17,148 Net loss attributable to common stockholders ( 3 ) (12,384 ) (14,709 ) (14,061 ) (16,762 ) Net loss per share — basic and diluted ( 2 ) (0.30 ) (0.30 ) (0.28 ) (0.33 ) 201 6 Operating expenses (1) $ 12,970 $ 30,483 $ 10,792 $ 10,590 Net loss attributable to common stockholders (3) (12,887 ) (25,132 ) (11,762 ) (10,512 ) Net loss per share — basic and diluted(2) (0.81 ) (1.57 ) (0.52 ) (0.47 ) ( 1 Operating expenses for the three March 31, 2016 $1.6 $2.3 January 2016. three June 30, 2016 $19.7 $1.5 8 ( 2 Basic and diluted net loss per share for all periods presented have been adjusted retroactively to reflect the 1 6 ( 3 Net loss attributable to common stockholders for the three June 30, 2016 $6.9 8 $1.6 three September 30, 2016 $1.0

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation These consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (U.S. GAAP) and reflect the following significant accounting policies.
Reverse Stock Split, Policy [Policy Text Block]	Change in Authorized Shares and Reverse Stock Split On November 18, 2016, 200,000,000 66,666,667 33,333,333 66,666,667 June 8, 2017, 66,666,667 130,000,000. On November 29, 2016, one six six ’s common stock were combined into one 1 6
Consolidation, Policy [Policy Text Block]	Basis of consolidation The Company ’s consolidated financial statements include the accounts of the company and its wholly-owned subsidiaries, including Cascadian Therapeutics (Australia) Pty Ltd, Protocell Therapeutics Inc., Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira BV and Oncothyreon Luxembourg. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	Accounting estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make complex and subjective judgments and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. By their nature, these judgments are subject to an inherent degree of uncertainty and as a consequence actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents Cash equivalents include short-term, highly liquid investments that are readily convertible to known amounts of cash with original maturities of 90 December 31, 2017, $10.3 $6.5 December 31, 2016, $7.2 $6.6
Investment, Policy [Policy Text Block]	Investments Investments are classified as available-for-sale securities and are carried at fair value with unrealized temporary holding gains and losses excluded from net income or loss and reported in other comprehensive income or loss and as a net amount in accumulated other comprehensive income or loss until realized. Available-for-sale securities are written down to fair value through income whenever it is necessary to reflect other-than-temporary impairments. The Company determined that the unrealized losses on its marketable securities as of December 31, 2017 not one 12 not may third third third Amortized Cost Gross Unrealized Gross Unrealized Fair Value (In thousands) As of December 31, 2017: Cash $ 10,300 $ — $ — $ 10,300 Money market funds 6,477 — — 6,477 Debt securities of U.S. government agencies 57,851 — (98 ) 57,753 Corporate bonds 26,479 — (21 ) 26,458 Total $ 101,107 $ — $ (119 ) $ 100,988 As of December 31, 2016: Cash $ 7,162 $ — $ — $ 7,162 Money market funds 6,559 — — 6,559 Debt securities of U.S. government agencies 38,387 1 (10 ) 38,378 Corporate bonds 10,711 — (5 ) 10,706 Total $ 62,819 $ 1 $ (15 ) $ 62,805 The following table summarizes the aggregate related fair value of investments with unrealized losses by investment category: As of December 31, 2017 As of December 31, 2016 Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses (In thousands) Debt securities of U.S. government agencies $ 55,276 $ (98 ) $ 31,990 $ (10 ) Corporate bonds 26,458 (21 ) 8,955 (5 ) Total $ 81,734 $ (119 ) $ 40,945 $ (15 ) The following table summarizes the Company ’s available for sale securities by contractual maturity: As of December 31, 2017 As of December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value (In thousands) Less than one year $ 83,080 $ 82,977 $ 55,657 $ 55,643 Greater than one year but less than five years 7,727 7,711 — — Total $ 90,807 $ 90,688 $ 55,657 $ 55,643
Warrants [Policy Text Block]	Warrants Warrants issued in connection with the Company ’s September 2010 September 2010 October 12, 2015. No December 31, 2017 2016.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts and other receivables Accounts and other receivables are reviewed whenever circumstances indicate that the carrying amount of the receivable may not As of December 31, 2017, not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment, depreciation and amortization Property and equipment are recorded at cost and depreciated over their estimated useful lives on a straight-line basis, as follows: Scientific and office equipment 5 years Computer software and equipment 3 years Leasehold improvements and leased equipment Shorter of useful life or the term of the lease
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-lived assets Long-lived assets, such as property and equipment , are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third $0.1 December 31, 2017. No December 31, 2016 2015.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite-lived i ntangible a ssets — IPR&D Intangible assets related to In Process Research & Development (IPR&D) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon completion of the project, the Company will make a separate determination of useful life of the IPR&D and the related amortization will be recorded as an expense over the estimated useful life. If the IPR&D is abandoned, the carrying value of the asset will be expensed. During the period the assets are considered indefinite-lived, they will not October 1 may
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill is not October 1 may No
Other Liabilities Policy [Policy Text Block]	Other liabilities Other liabilities include the long-term portion of accrued milestone payments and deferred rent. Certain milestone payments under our previous agreement with STC.UNM are accrued on a straight-line basis from initiation of the license agreement to the milestone payment date. Also included in this line item is the long-term portion of deferred rent. Rent expense is recognized on a straight-line basis over the term of the lease. Lease incentives, including rent holidays provided by lessors, and rent escalation provisions are accounted for as deferred rent.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable, and collection is reasonably assured.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development expenses include personnel and facility related expenses, which includes depreciation and amortization, outside contract services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. In instances where the Company enters into agreements with third may may The Company ’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with numerous clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third may
Earnings Per Share, Policy [Policy Text Block]	Income or loss per share Basic net loss per share is calculated by dividing net loss attributable to common stockholders, which may 2010 December 31, 2017, 2016 2015, 1 6 6
Income Tax, Policy [Policy Text Block]	Income taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future income tax consequences attributable to differences between the carrying amounts and tax bases of assets and liabilities and losses carried forward and tax credits. Deferred tax assets and liabilities are measured using enacted tax rates and laws applicable to the years in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to the extent that it is more likely than not not The Company recognizes the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company does not twelve none,
Comprehensive Income, Policy [Policy Text Block]	Accumulated other comprehensive income (loss) Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company ’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. There were no years ended December 31, 2017, 2016 2015. December 31, 2017, 2016 2015: Net U nrealized G ains/(losses) on S ale Foreign Currency Adjustment Accumulated Other (In thousands) Balance at December 31, 2014 $ (25 ) $ (5,066 ) $ (5,091 ) Other comprehensive income 27 — 27 Balance at December 31, 2015 $ 2 $ (5,066 ) $ (5,064 ) Other comprehensive loss (16 ) — (16 ) Balance at December 31, 2016 $ (14 ) $ (5,066 ) $ (5,080 ) O ther comprehensive loss (105 ) — (105 ) Balance at December 31, 2017 $ (119 ) $ (5,066 ) $ (5,185 )
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based compensation The Company recognizes in the statements of operations the estimated grant date fair value of share-based compensation awards granted to employees over the requisite service period. Share-based compensation expense in the consolidated statements of operations is recorded on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period, with the offset to additional paid-in capital. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted to employees. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. On June 23, 2016, ’s stockholders approved a new 2016 2016 2016 June 8, 2017, 2016 2016 1,200,905 7,900,905 For non-employee directors, the Company sponsors a RSU Plan that was established in 2005. October 2011, 25% ’ U.S. federal income tax obligation with respect to the vested RSUs. This amendment resulted in the RSUs being classified as a liability. The outstanding RSU awards are required to be re-measured at each reporting date until settlement of the award, and changes in valuation are recorded as compensation expense for the period. To the extent that the liability recorded in the balance sheet is less than the original award value, the difference is recognized in equity. The Company uses the closing share price of its shares on the Nasdaq Global Market at the reporting or settlement date to determine the fair value of RSUs. In June 2014, 83,333 June 23, 2016, 2016 2016 The Company maintains an ESPP under which a total of 150,000 For additional information regarding share-based compensation, see “Note 7
Business Combinations Policy [Policy Text Block]	Business Combinations In a business combination, the Company determines if the acquired property and activities meet the definition of a business under current accounting guidance. If the combination meets the definition of a business, the Company measures the significance of the combination to determine the required reporting and disclosure requirements for the transaction. Business combinations are required to be accounted for under the acquisition method which requires that identifiable assets acquired, liabilities assumed and any non-controlling interest in the acquiree be recognized and measured as of the acquisition date at fair value. In addition, all consideration transferred must be measured at its acquisition-date fair value. When necessary, the Company uses a third not
Segment Reporting, Policy [Policy Text Block]	Segment information The Company operates in a single business segment — research and development of therapeutic products for the treatment of cancer.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In January 2017, 2017 04, Intangibles – Goodwill and Other (Topic 350 2 December 15, 2019. January 1, 2017. may In August 2016, 2016 15, 230 a consensus of the FASB’s Emerging Issues Task Force. The standard is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard addresses the classification of cash flows related to ( 1 2 zero 3 4 5 6 7 December 15, 2017, January 1, 2018. not In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, December 15, 2016, January 1, 2017. not In February 2016, 2016 02, 842 December 15, 2018, may In January 2016, 2016 01, – Overall (Subtopic 825 10 not not not 2016 01 December 15, 2017, not January 1, 2018. not In August 2015, 2015 14, 606 —Deferral of the Effective Date, which defers by one 2014 09, December 15, 2017, December 15, 2016, January 1, 2018. not not

Note 2 - Significant Accounti24

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Unrealized Gain (Loss) on Investments [Table Text Block]	Amortized Cost Gross Unrealized Gross Unrealized Fair Value (In thousands) As of December 31, 2017: Cash $ 10,300 $ — $ — $ 10,300 Money market funds 6,477 — — 6,477 Debt securities of U.S. government agencies 57,851 — (98 ) 57,753 Corporate bonds 26,479 — (21 ) 26,458 Total $ 101,107 $ — $ (119 ) $ 100,988 As of December 31, 2016: Cash $ 7,162 $ — $ — $ 7,162 Money market funds 6,559 — — 6,559 Debt securities of U.S. government agencies 38,387 1 (10 ) 38,378 Corporate bonds 10,711 — (5 ) 10,706 Total $ 62,819 $ 1 $ (15 ) $ 62,805
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]	As of December 31, 2017 As of December 31, 2016 Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses (In thousands) Debt securities of U.S. government agencies $ 55,276 $ (98 ) $ 31,990 $ (10 ) Corporate bonds 26,458 (21 ) 8,955 (5 ) Total $ 81,734 $ (119 ) $ 40,945 $ (15 )
Investments Classified by Contractual Maturity Date [Table Text Block]	As of December 31, 2017 As of December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value (In thousands) Less than one year $ 83,080 $ 82,977 $ 55,657 $ 55,643 Greater than one year but less than five years 7,727 7,711 — — Total $ 90,807 $ 90,688 $ 55,657 $ 55,643
Schedule of Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]	Scientific and office equipment 5 years Computer software and equipment 3 years Leasehold improvements and leased equipment Shorter of useful life or the term of the lease
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Net U nrealized G ains/(losses) on S ale Foreign Currency Adjustment Accumulated Other (In thousands) Balance at December 31, 2014 $ (25 ) $ (5,066 ) $ (5,091 ) Other comprehensive income 27 — 27 Balance at December 31, 2015 $ 2 $ (5,066 ) $ (5,064 ) Other comprehensive loss (16 ) — (16 ) Balance at December 31, 2016 $ (14 ) $ (5,066 ) $ (5,080 ) O ther comprehensive loss (105 ) — (105 ) Balance at December 31, 2017 $ (119 ) $ (5,066 ) $ (5,185 )

Note 3 - Fair Value Measureme25

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	December 31, 2017 December 31, 201 6 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (In thousands) Financial Assets: Money market funds $ 6,477 $ — $ — $ 6,477 $ 6,559 $ — $ — $ 6,559 Debt securities of U.S. government agencies — 57,753 — 57,753 — 38,378 — 38,378 Corporate bonds — 26,458 — 26,458 — 10,706 — 10,706 $ 6,477 $ 84,211 $ — $ 90,688 $ 6,559 $ 49,084 $ — $ 55,643 Financial Liability: Restricted Share Units $ 355 $ — $ — $ 355 $ 352 $ — $ — $ 352

Note 4 - Property and Equipme26

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	201 7 Cost Accumulated Depreciation Net Carrying (In thousands) Scientific equipment $ 1,192 $ (939 ) $ 253 Leasehold improvements 1,868 (1,829 ) 39 Computer software and equipment 423 (325 ) 98 Office equipment 364 (98 ) 266 $ 3,847 $ (3,191 ) $ 656 201 6 Cost Accumulated Depreciation Net Carrying (In thousands) Scientific equipment $ 3,077 $ (2,241 ) $ 836 Leasehold improvements 1,627 (1,269 ) 358 Computer software and equipment 390 (315 ) 75 Office equipment 170 (37 ) 133 $ 5,264 $ (3,862 ) $ 1,402

Note 6 - Share Capital (Tables)

Note 6 - Share Capital (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	201 7 201 6 Shares Underlying Shares Underlying Balance, beginning of year 841,449 841,449 Balance, end of year 841,449 841,449
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, 201 7 201 6 201 5 (in thousands, except share and per share amounts) Numerator: Net loss attributable to common stockholders used to compute net loss per share Basic $ (57,916 ) $ (60,293 ) $ (32,581 ) Diluted $ (57,916 ) $ (60,293 ) $ (32,581 ) Denominator: Weighted average shares outstanding used to compute net loss per share: Basic 47,966,493 19,264,121 16,102,860 Diluted 47,966,493 19,264,121 16,102,860 Net loss per share —basic and diluted $ (1.21 ) $ (3.13 ) $ (2.02 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years Ended December 31, 201 7 201 6 201 5 Director and employee stock options 3,170,542 1,866,711 1,225,194 Warrants 841,449 841,449 841,449 Convertible preferred stock (as converted to common stock): Series A 416,673 1,666,697 1,666,697 Series B 888,851 888,851 888,851 Series C 1,250,022 1,250,022 1,250,022 Series D 2,875,055 2,875,055 — Series E 1,818,000 — — Employee restricted share units 327,820 — — Non-employee director restricted share units 95,999 81,619 38,157 Employee stock purchase plan 4,237 1,830 449
Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Prices Shares Underlying Expiry Date $ 18.48 8,116 February 8, 2018 $ 30.00 833,333 December 5, 2018 841,449
Warrants Classified as Equity [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Years Ended December 31, 201 7 201 6 Shares underlying warrants outstanding classified as equity 841,449 841,449

Note 7 - Share-based Compensa28

Note 7 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2017 2016 2015 Expected dividend rate 0.00 % 0.00 % 0.00 % Expected volatility 76.47 % 74.63 % 72.15 % Risk-free interest rate 1.94 % 1.46 % 1.63 % Expected life of options in years 5.69 6.22 6.00
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Stock Options Weighted Average Weighted Average Aggregate Intrinsic Value In US dollars ($US): Outstanding at January 1, 2017 1,866,711 $ 13.36 Granted 1,508,623 4.27 Exercised — — Forfeited (100,680 ) 13.08 Expired (104,112 ) 23.16 Outstanding at December 31, 2017 3,170,542 $ 8.73 7.57 $ 1,128 Vested or expected to vest at December 31, 2017 2,940,709 $ 9.02 7.45 $ 976 Vested and exercisable at December 31, 2017 1,096,633 $ 14.57 5.25 $ —
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Restricted Share Units to Employees Restricted Share Weighted Average Non-vested at January 1, 2017 — $ — Granted 335,920 4.24 Forfeited (8,100 ) 4.55 Non-vested at December 31, 2017 327,820 $ 3.70 Expected to vest at December 31, 2017 327,820 $ 3.70 Restricted Share Units to Non-Employee Directors Restricted Share Weighted Average Non-vested at January 1, 2017 54,348 $ 4.31 Granted 95,999 3.65 Converted (54,348 ) 3.86 Non-vested at December 31, 2017 95,999 $ 3.70 Expected to vest at December 31, 2017 95,999 $ 3.70 Restricted Share Units Restricted Share Weighted Average Non-vested at January 1, 2017 27,271 $ 4.31 Converted (27,271 ) 3.87 Non-vested at December 31, 2017 — $ — Expected to vest at December 31, 2017 — $ —
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]	Shares Issued for the Year s Ended December 31 , Purchase Prices 2017 2016 2015 $ 2.81 65,437 — — $ 4.45 — 10,900 — $ 5.10 — 8,261 — $ 8.94 — — 4,698 $ 9.72 — — 1,899 $ 11.10 — — 4,656 Total 65,437 19,161 11,253

Note 9 - Net Investment and O29

Note 9 - Net Investment and Other Income (Expense) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Years Ended December 31, 201 7 201 6 201 5 (In thousands) Investment income, net $ 1,065 $ 240 $ 73 Net foreign exchange gain (loss) (5 ) 1 (5 ) Gain (loss) on sale of equipment 170 (69 ) 7 Gain on sale of investment — — — Impairment expense (75 ) — — Other income — 50 5 Total investment and other income, net $ 1,155 $ 222 $ 80

Note 10 - Income Tax (Tables)

Note 10 - Income Tax (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2017 2016 2015 (In thousands) Current income tax expense (benefit) $ — $ — $ — Deferred income tax expense (benefit) — (6,908 ) — Total income tax expense (benefit) $ — $ (6,908 ) $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2017 2016 201 5 Tax benefit at statutory rate 35.0 % 35.0 % 35.0 % Change in fair value of warrant liability 0.0 0.0 0.1 Stock based compensation (1.6 ) (0.9 ) 0.8 Other 0.0 0.4 0.4 Tax law changes (88.1 ) 0.0 0.0 Change in valuation allowance 54.7 (23.7 ) (40.0 ) Net operating loss expiration and true ups 0.0 0.0 3.7 Income tax benefit (provision) 0.0 % 10.8 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2017 201 6 (In thousands) Deferred tax assets Accrued expenses and other $ 623 $ 1,510 Tax benefits from losses carried forward and tax credits 126,552 147,001 Stock based compensation 2,547 4,119 Intangible assets 5,312 9,776 Other 242 207 Total deferred tax assets $ 135,276 $ 162,613 Valuation allowance (135,180 ) (162,414 ) Net deferred tax assets 96 199 Deferred tax liabilities Prepaid expenses 96 199 Intangible asset — — Total deferred tax liabilities 96 199 Net deferred tax liability $ — $ —
Summary of Income Tax Contingencies [Table Text Block]	201 7 2016 2015 (In thousands) Balance at January 1 $ 662 $ 662 $ 545 Increase related to prior year tax positions 117 Decrease related to current year tax positions — — — Lapses of statute of limitations — — — Balance at December 31 $ 662 $ 662 $ 662

Note 11 - Contingencies, Comm31

Note 11 - Contingencies, Commitments, and Guarantees (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 201 8 $ 849 2019 1,368 2020 1,410 2021 1,454 2022 499 Thereafter — Total $ 5,580

Note 14 - Condensed Quarterly32

Note 14 - Condensed Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	Three Months Ended, March 31 June 30 September 30 December 31 (In thousands, except per share data) 201 7 Operating expenses ( 1 ) $ 11,562 $ 15,021 $ 14,358 $ 17,148 Net loss attributable to common stockholders ( 3 ) (12,384 ) (14,709 ) (14,061 ) (16,762 ) Net loss per share — basic and diluted ( 2 ) (0.30 ) (0.30 ) (0.28 ) (0.33 ) 201 6 Operating expenses (1) $ 12,970 $ 30,483 $ 10,792 $ 10,590 Net loss attributable to common stockholders (3) (12,887 ) (25,132 ) (11,762 ) (10,512 ) Net loss per share — basic and diluted(2) (0.81 ) (1.57 ) (0.52 ) (0.47 )

Note 1 - Description of Busin33

Note 1 - Description of Business (Details Textual) - $ / shares	Jan. 31, 2018	Jan. 30, 2018
Seattle Genetics, Inc. and Valley Acquistion Sub, Inc. [Member] | Subsequent Event [Member]
Business Acquisition, Share Price	$ 10	$ 10

Note 2 - Significant Accounti34

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	Nov. 29, 2016shares	Nov. 18, 2016shares	Jun. 30, 2014shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Jun. 08, 2017shares	Jun. 07, 2017shares	Nov. 28, 2016shares	Nov. 17, 2016shares	Jun. 23, 2016shares	Jun. 03, 2010shares
Common Stock, Shares Authorized | shares	66,666,667	66,666,667		130,000,000	66,666,667		130,000,000	66,666,667	33,333,333	200,000,000
Cash				$ 10,300	$ 7,162
Money Market Funds and US Government Securities, At Carrying Value				6,500	6,600
Warrant Liability				0	0
Impairment of Long-Lived Assets Held-for-use				100	0	$ 0
Goodwill, Impairment Loss				$ 0	$ 0	$ 0
Number of Operating Segments				1
The 2016 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance | shares							7,900,905	1,200,905			1,200,905
Restricted Share Unit Plan [Member] | Restricted Stock Units (RSUs) [Member]
Value Shares Withheld Restricted Share Unit, Percentage				25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | shares			83,333
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares				150,000								150,000
Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6	6		6	6

Note 2 - Significant Accounti35

Note 2 - Significant Accounting Policies - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash, Amortized cost	$ 10,300	$ 7,162
Money market funds, Amortized cost	6,477	6,559
Available-for-sale securities, Gross unrealized gains		1
Available-for-sale securities, Gross unrealized losses	(119)	(15)
Total, Amortized cost	101,107	62,819
Total, Fair value	100,988	62,805
US Government Agencies Debt Securities [Member]
Available-for-sale securities, Amortized cost	57,851	38,387
Available-for-sale securities, Gross unrealized gains		1
Available-for-sale securities, Gross unrealized losses	(98)	(10)
Available-for-sale securities,Fair value	57,753	38,378
Corporate Debt Securities [Member]
Available-for-sale securities, Amortized cost	26,479	10,711
Available-for-sale securities, Gross unrealized gains
Available-for-sale securities, Gross unrealized losses	(21)	(5)
Available-for-sale securities,Fair value	$ 26,458	$ 10,706

Note 2 - Significant Accounti36

Note 2 - Significant Accounting Policies - Summary of Available-for-sale Securities with Unrealized Losses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair value	$ 81,734	$ 40,945
Gross unrealized losses	(119)	(15)
US Government Agencies Debt Securities [Member]
Fair value	55,276	31,990
Gross unrealized losses	(98)	(10)
Corporate Debt Securities [Member]
Fair value	26,458	8,955
Gross unrealized losses	$ (21)	$ (5)

Note 2 - Significant Accounti37

Note 2 - Significant Accounting Policies - Summary of Available-for-sale Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Less than one year, Amortized cost	$ 83,080	$ 55,657
Less than one year, Fair value	82,977	55,643
Greater than one year but less than five years, Amortized cost	7,727	0
Greater than one year but less than five years, Fair value	7,711	0
Total, Amortized cost	90,807	55,657
Total, Fair value	$ 90,688	$ 55,643

Note 2 - Significant Accounti38

Note 2 - Significant Accounting Policies - Property and Equipment Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2017
Scientific and Office Equipment [Member]
Property and equipment, useful life (Year)	5 years
Computer Software and Equipment [Member]
Property and equipment, useful life (Year)	3 years
Leaseholds and Leasehold Improvements [Member]
Leasehold improvements and leased equipment	Shorter of useful life or the term of the lease

Note 2 - Significant Accounti39

Note 2 - Significant Accounting Policies - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 74,357	$ 83,735	$ 91,266
Other comprehensive income	(105)	(16)	27
Balance	109,036	74,357	83,735
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Balance	(14)	2	(25)
Other comprehensive income	(105)	(16)	27
Balance	(119)	(14)	2
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(5,066)	(5,066)	(5,066)
Other comprehensive income	0	0	0
Balance	(5,066)	(5,066)	(5,066)
AOCI Attributable to Parent [Member]
Balance	(5,080)	(5,064)	(5,091)
Other comprehensive income	(105)	(16)	27
Balance	$ (5,185)	$ (5,080)	$ (5,064)

Note 3 - Fair Value Measureme40

Note 3 - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Financial assets	$ 90,688	$ 55,643
Restricted Share Unit Plan [Member]
Financial liabilities	355	352
Fair Value, Inputs, Level 1 [Member]
Financial assets	6,477	6,559
Fair Value, Inputs, Level 1 [Member] | Restricted Share Unit Plan [Member]
Financial liabilities	355	352
Fair Value, Inputs, Level 2 [Member]
Financial assets	84,211	49,084
Money Market Funds [Member]
Financial assets	6,477	6,559
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Financial assets	6,477	6,559
US Government Agencies Debt Securities [Member]
Financial assets	57,753	38,378
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financial assets	57,753	38,378
Corporate Debt Securities [Member]
Financial assets	26,458	10,706
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financial assets	$ 26,458	$ 10,706

Note 4 - Property and Equipme41

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Depreciation, Depletion and Amortization	$ 956	$ 642	$ 613
Accelerated Depreciation Expense	$ 300

Note 4 - Property and Equipme42

Note 4 - Property and Equipment - Cost, Accumulated Depreciation and Amortization and Net Carrying Value of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Cost	$ 3,847	$ 5,264
Accumulated Depreciation and Amortization	(3,191)	(3,862)
Property and equipment, net	656	1,402
Scientific and Office Equipment [Member]
Cost	1,192	3,077
Accumulated Depreciation and Amortization	(939)	(2,241)
Property and equipment, net	253	836
Leasehold Improvements [Member]
Cost	1,868	1,627
Accumulated Depreciation and Amortization	(1,829)	(1,269)
Property and equipment, net	39	358
Computer Software and Equipment [Member]
Cost	423	390
Accumulated Depreciation and Amortization	(325)	(315)
Property and equipment, net	98	75
Office Equipment [Member]
Cost	364	170
Accumulated Depreciation and Amortization	(98)	(37)
Property and equipment, net	$ 266	$ 133

Note 5 - Intangible Asset Imp43

Note 5 - Intangible Asset Impairment (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Impairment of Intangible Assets (Excluding Goodwill)			$ 19,738
Income Tax Expense (Benefit)	$ (6,900)		(6,908)
In Process for Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill)			$ 19,700

Note 6 - Share Capital (Details

Note 6 - Share Capital (Details Textual)		Jan. 27, 2017USD ($)$ / shares$ / itemshares	Nov. 29, 2016shares	Nov. 18, 2016shares	Jun. 28, 2016USD ($)$ / shares$ / itemshares	May 14, 2015$ / sharesshares	Feb. 18, 2015USD ($)$ / sharesshares	Feb. 11, 2015USD ($)$ / shares$ / itemshares	Jul. 31, 2017shares	Jun. 30, 2013shares	Feb. 28, 2011shares	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2017USD ($)$ / sharesshares		Dec. 31, 2016USD ($)shares		Dec. 31, 2015USD ($)shares		Jun. 08, 2017shares	Jun. 07, 2017shares	Dec. 31, 2016CAD / shares	Dec. 31, 2016USD ($)$ / sharesshares	Nov. 28, 2016shares	Nov. 17, 2016shares	Jun. 02, 2016USD ($)$ / shares	Sep. 22, 2014$ / sharesshares
Capital Stock, Total Number of Shares Authorized														140,012,500
Common Stock, Shares Authorized			66,666,667	66,666,667										130,000,000						130,000,000	66,666,667		66,666,667	33,333,333	200,000,000
Common Stock, Par or Stated Value Per Share | $ / shares														$ 0.0001									$ 0.0001
Preferred Stock, Shares Authorized														10,000,000	[1],[2]								10,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares														$ 0.0001									$ 0.0001
Class UA Preferred Stock, Liquidation Preference, Percentage														20.00%
Class UA Preferred Stock, Liquidation Preference | CAD / shares																						CAD 100
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,250,024
Stock Issued During Period, Shares, New Issues								2,250,000
Proceeds from Issuance or Sale of Equity, Gross | $		$ 94,000,000
Common Stock, Value, Issued | $														$ 353,852,000									$ 353,849,000
Class of Warrant or Right, Issued in Period										833,333	8,116
Share Price | $ / shares								$ 9						$ 3.70
Proceeds from Issuance of Common Stock, Gross | $					$ 46,000,000		$ 24,000,000	$ 20,300,000
Payments of Stock Issuance Costs | $		6,000,000			2,700,000		1,600,000
Proceeds from Issuance or Sale of Equity | $		$ 88,000,000			$ 43,300,000		$ 22,400,000
Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio			6	6										6		6
Underwriter Options [Member]
Share Price | $ / shares							$ 9
Proceeds from Issuance or Sale of Equity | $							$ 1,700,000
Additional Shares Granted Gross							199,943	337,500
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	[3]													1,250,024
Stock Issued During Period, Shares, New Issues		26,659,300			6,708,333									26,659,300	[3]	6,708,333	[3]	2,449,943	[3]
Share Price | $ / shares		$ 3.30			$ 4.80
Proceeds from Issuance of Common Stock, Gross | $		$ 88,000,000			$ 32,200,000
Common Stock [Member] | Sales Agreement with Cowen and Company [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																										$ 0.0001
Aggregate Gross Sales Proceeds Under Sales Agreement | $																										$ 50,000,000
Common Stock [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues		3,477,300			875,000
Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities														(7,500)
Class UA Preferred Stock [Member]
Preferred Stock, Shares Authorized														12,500									12,500
Preferred Stock, No Par Value | $ / shares														$ 0
Preferred Stock, Shares Outstanding														12,500									12,500
Preferred Stock, Shares Issued														12,500									12,500
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding														2,500									10,000
Conversion of Stock, Shares Converted									7,500
Preferred Stock Permitted to Issue Shares																											10,000
Convertible Preferred Stock, Shares Issued upon Conversion																											166.67
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion																											4.99%
Preferred Stock, Liquidation Preference Per Share | $ / shares																											$ 0.0001
Preferred Stock, Shares Issued														2,500									10,000
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized								5,333
Preferred Stock, Shares Outstanding														5,333									5,333
Convertible Preferred Stock, Shares Issued upon Conversion								166.67
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion								4.99%
Preferred Stock, Liquidation Preference Per Share | $ / shares								$ 0.0001
Stock Issued During Period, Shares, New Issues								1,333
Preferred Stock, Shares Issued														5,333									5,333
Series B Convertible Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues	[3]																	(666,667)
Series B Convertible Preferred Stock [Member] | Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion								166.67
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion								4.99%
Stock Issued During Period, Shares, New Issues								1,333										5,333
Convertible Preferred Stock Price Per Share | $ / item								1,500
Proceeds from Issuance of Convertible Preferred Stock, Gross | $								$ 2,000,000
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding														7,500									7,500
Preferred Stock, Shares Issued														7,500									7,500
Series C Convertible Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues	[3]																	(1,250,000)
Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues																		7,500
Series C Convertible Preferred Stock [Member] | Affiliates of BVF [Member]
Convertible Preferred Stock, Shares Issued upon Conversion						166.67
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion						9.99%
Preferred Stock, Liquidation Preference Per Share | $ / shares						$ 0.0001
Stock Issued During Period, Shares, New Issues						7,500
Common Stock Exchanged for Shares of Convertible Preferred Stock						1,245,022
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized					17,250
Preferred Stock, Shares Outstanding														17,250									17,250
Preferred Stock Permitted to Issue Shares					17,250
Preferred Stock, Shares Issued														17,250									17,250
Convertible Preferred Stock Price Per Share | $ / item					800
Beneficial Conversion Feature Associated with Convertible Preferred Stock | $																$ 2,600,000
Adjustments to Additional Paid in Capital, Other | $																$ 2,600,000
Accretion on Beneficial Conversion Feature Associated with Convertible Preferred Stock | $												$ 1,000,000	$ 1,600,000
Proceeds from Issuance of Convertible Preferred Stock, Gross | $					$ 13,800,000
Series D Convertible Preferred Stock [Member] | Exchange Agreement With Certain Affiliates of Biotechnology Value Fund [Member]
Preferred Stock Permitted to Issue Shares					17,250
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion					19.99%
Convertible Preferred Stock Price Per Share | $ / item					800
Proceeds from Issuance of Convertible Preferred Stock, Gross | $					$ 13,800,000
Convertible Preferred Stock to Be Converted					1,000
Series D Convertible Preferred Stock [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues																17,250
Series D Convertible Preferred Stock [Member] | Affiliates of BVF [Member]
Convertible Preferred Stock, Shares Issued upon Conversion					166.67
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion					19.99%
Preferred Stock, Liquidation Preference Per Share | $ / shares					$ 0.0001
Stock Issued During Period, Shares, New Issues					17,250
Convertible Preferred Stock Price Per Share | $ / item					800
Proceeds from Issuance or Sale of Equity, Gross | $					$ 13,800,000
Percentage of Holders Election					19.99%
Days of Notice to Company for Increase of Percentage in Holders Election					61 days
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		1,818
Preferred Stock, Shares Outstanding														1,818									0
Preferred Stock Permitted to Issue Shares		1,818
Convertible Preferred Stock, Shares Issued upon Conversion		1,000
Maximum Ownership Percentage of Common Shares Outstanding Post Conversion		19.99%
Preferred Stock, Liquidation Preference Per Share | $ / shares		$ 0.0001
Stock Issued During Period, Shares, New Issues		1,818
Preferred Stock, Shares Issued														1,818									0
Convertible Preferred Stock Price Per Share | $ / item		3,300
Proceeds from Issuance or Sale of Equity, Gross | $		$ 6,000,000
Percentage of Holders Election		19.99%
Days of Notice to Company for Increase of Percentage in Holders Election		61 years
Adjustments to Additional Paid in Capital, Other | $		$ 1,000,000
Accretion on Beneficial Conversion Feature Associated with Convertible Preferred Stock | $		1,000,000												$ 982,000		$ 2,588,000
Proceeds from Issuance of Convertible Preferred Stock, Gross | $		$ 6,000,000
Series E Convertible Preferred Stock [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues														1,818
Common Class A [Member]
Common Stock, Value, Issued | $														$ 5,060									$ 2,256
[1]	The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing
[2]	The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing
[3]	Common stock shares for the years ended December 31, 2015 and 2014 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

Note 6 - Share Capital - Summar

Note 6 - Share Capital - Summary and Changes of Outstanding Warrants (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Shares underlying outstanding warrants (in shares)	841,449	841,449

Note 6 - Share Capital - Summ46

Note 6 - Share Capital - Summary Information Regarding Warrants Outstanding (Details) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Shares underlying outstanding warrants (in shares)	841,449	841,449
February 2015 Warrants [Member]
Shares underlying outstanding warrants (in shares)	8,116
Warrants, exercise price (in dollars per share)	$ 18.48
December 2015 Warrants [Member]
Shares underlying outstanding warrants (in shares)	833,333
Warrants, exercise price (in dollars per share)	$ 30

Note 6 - Share Capital - Shares

Note 6 - Share Capital - Shares Underlying Outstanding Warrants Classified as Liabilities and Equity (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Shares underlying outstanding warrants (in shares)	841,449	841,449
Warrants Classified as Equity [Member]
Shares underlying outstanding warrants (in shares)	841,449	841,449

Note 6 - Share Capital - Reconc

Note 6 - Share Capital - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income or Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2017	[1]	Sep. 30, 2017	[1]	Jun. 30, 2017	[1]	Mar. 31, 2017	[1]	Dec. 31, 2016	[1]	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Net loss attributable to common stockholders																	$ (57,916)		$ (60,293)		$ (32,581)
Diluted																	$ (57,916)		$ (60,293)		$ (32,581)
Basic (in shares)																	47,966,493		19,264,121		16,102,860
Diluted (in shares)																	47,966,493		19,264,121		16,102,860
Net loss per share basic and diluted (in dollars per share)	$ (0.33)		$ (0.28)		$ (0.30)		$ (0.30)		$ (0.47)		$ (0.52)		$ (1.57)		$ (0.81)		$ (1.21)	[2]	$ (3.13)	[2]	$ (2.02)	[2]
[1]	Basic and diluted net loss per share for all periods presented have been adjusted retroactively to reflect the 1-for-6 reverse stock split.
[2]	Basic and diluted net loss per share, and shares to used compute basic and diluted net loss per share for the year ended December 31, 2015 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

Note 6 - Share Capital - Net Lo

Note 6 - Share Capital - Net Loss Per Share - Number of Shares Excluded from the Number of Shares Used to Calculate Diluted Net Income or Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Director and Employee Stock Options [Member]
Anti-dilutive shares (in shares)	3,170,542	1,866,711	1,225,194
Warrant [Member]
Anti-dilutive shares (in shares)	841,449	841,449	841,449
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares (in shares)	416,673	1,666,697	1,666,697
Series B Convertible Preferred Stock [Member]
Anti-dilutive shares (in shares)	888,851	888,851	888,851
Series C Convertible Preferred Stock [Member]
Anti-dilutive shares (in shares)	1,250,022	1,250,022	1,250,022
Series D Convertible Preferred Stock [Member]
Anti-dilutive shares (in shares)	2,875,055	2,875,055
Series E Convertible Preferred Stock [Member]
Anti-dilutive shares (in shares)	1,818,000
Employee Restricted Shares Units [Member]
Anti-dilutive shares (in shares)	327,820
Non Employee Director Restricted Share Units [Member]
Anti-dilutive shares (in shares)	95,999	81,619	38,157
Employee Stock Purchase Plan [Member]
Anti-dilutive shares (in shares)	4,237	1,830	449

Note 7 - Share-based Compensa50

Note 7 - Share-based Compensation (Details Textual) - USD ($)	Apr. 04, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 08, 2017	Jun. 07, 2017	Jun. 23, 2016	Feb. 11, 2015	Jun. 03, 2010
Allocated Share-based Compensation Expense		$ 3,200,000	$ 4,800,000	$ 2,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 5,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 270 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 2.81	$ 4.53	$ 13.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 10,900,000	$ 10,600,000	$ 8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0	0	3,324
Proceeds from Stock Options Exercised		$ 0	$ 0	$ 34,568
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 0	$ 0	39,859
Share Price		$ 3.70						$ 9
The 2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Common Stock, Capital Shares Reserved for Future Issuance					7,900,905	1,200,905	1,200,905
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		5,723,523
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,508,623
The 2016 Equity Incentive Plan [Member] | Award Originated Under 2016 EIP [Member]
Common Stock, Capital Shares Reserved for Future Issuance							1,050,000
The 2016 Equity Incentive Plan [Member] | Award Transferred from Option Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							82,884
The 2016 Equity Incentive Plan [Member] | Award Transferred from RSU Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							68,021
The 2016 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		335,920
The 2016 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		95,999	54,348
Restricted Share Units Granted in Period, Total Fair Value		$ 350,000	$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		54,348
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 3.86
Stock Issued During Period, Shares, Restricted Stock Award, Gross		54,348
Shares for Tax Withholding for Restricted Share Unit Plan		13,590
Cash Paid for Tax Withholding for Share-based Compensation				$ 52,412
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options		$ 0
Stock Option Plan [Member] | Employee Stock Option [Member]
Maximum Fixed Reloading Percentage		10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			313,040
Stock Option Plan [Member] | Employee Stock Option [Member] | Options Granted Prior to January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		8 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Stock Option Plan [Member] | Employee Stock Option [Member] | Options Granted After January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		8 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Stock Option Plan [Member] | Employee Stock Option [Member] | Begin to Vest [Member] | Options Granted Prior to January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		1 year
Inducement Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	474,810
Inducement Grant [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Inducement Grant [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Inducement Grant [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
RSU Plan [Member] | Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		27,271		16,308
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 3.87	$ 18.36	$ 22.75
Shares for Tax Withholding for Restricted Share Unit Plan		6,819	2,723	4,078
Cash Paid for Tax Withholding for Share-based Compensation		$ 26,395	$ 20,098	$ 92,759
Contingent Right to Receive Common Stock, Percentage		75.00%
Contingent Right to Receive Common Stock, Shares		0.75
Value Shares Withheld Restricted Share Unit, Percentage		25.00%
Contigent Right To Receive Cash		0.25
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		27,271	10,893	16,308
RSU Plan [Member] | Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense		$ 11,980	$ 300,000	$ 600,000
RSU Plan [Member] | Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		1 year
RSU Plan [Member] | Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Employee Stock Purchase Plan [Member]
Allocated Share-based Compensation Expense		$ 200,000	$ 100,000	$ 100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 14 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		4,237
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		150,000							150,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate		15.00%
Employee Stock Purchase Plan Maximum Value of Compensation Per Employee		$ 25,000
Employee Stock Purchase Plan Purchase of Common Stock Percentage		85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee		15,000

Note 7 - Share-based Compensa51

Note 7 - Share-based Compensation - Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2017Rate	Dec. 31, 2016Rate	Dec. 31, 2015Rate
Expected dividend rate	0.00%	0.00%	0.00%
Expected volatility	76.47%	74.63%	72.15%
Risk-free interest rate (Rate)	1.94%	1.46%	1.63%
Expected life of options in years (Year)	5 years 251 days	6 years 80 days	6 years

Note 7 - Share-based Compensa52

Note 7 - Share-based Compensation - Summary of the Status of the Option Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0	3,324
The 2016 Equity Incentive Plan [Member]
Outstanding, Stock options (in shares)	1,866,711
Outstanding, Weighted average exercise price (in dollars per share)	$ 13.36
Granted, Stock options (in shares)	1,508,623
Granted, Weighted average exercise price (in dollars per share)	$ 4.27
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Exercised, Weighted average exercise price (in dollars per share)
Forfeited, Stock options (in shares)	(100,680)
Forfeited, Weighted average exercise price (in dollars per share)	$ 13.08
Expired, Stock options (in shares)	(104,112)
Expired, Weighted average exercise price (in dollars per share)	$ 23.16
Outstanding, Stock options (in shares)	3,170,542	1,866,711
Outstanding, Weighted average exercise price (in dollars per share)	$ 8.73	$ 13.36
Outstanding, Weighted average remaining contractual term (Year)	7 years 208 days
Outstanding, Aggregate intrinsic value	$ 1,128
Vested or expected to vest, Stock options (in shares)	2,940,709
Vested or expected to vest, Weighted average exercise price (in dollars per share)		$ 9.02
Vested or expected to vest, Weighted average remaining contractual term (Year)	7 years 164 days
Vested or expected to vest, Aggregate intrinsic value	$ 976
Vested and exercisable, Stock options (in shares)	1,096,633
Vested and exercisable, Weighted average exercise price (in dollars per share)	$ 14.57
Vested and exercisable, Weighted average remaining contractual term (Year)	5 years 91 days
Vested and exercisable, Aggregate intrinsic value

Note 7 - Share-based Compensa53

Note 7 - Share-based Compensation - Summary of the Status of the RSU Plan (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
The 2016 Equity Incentive Plan [Member]
Non-vested, Restricted share units (in shares)	0
Non-vested, Weighted average fair value per unit (in dollars per share)	$ 0
Granted, Restricted share units (in shares)	335,920
Granted, Weighted average fair value per unit (in dollars per share)	$ 4.24
Forfeited, Restricted share units (in shares)	(8,100)
Forfeited, Weighted average fair value per unit (in dollars per share)	$ 4.55
Non-vested, Restricted share units (in shares)	327,820	0
Non-vested, Weighted average fair value per unit (in dollars per share)	$ 3.70	$ 0
Expected to vest, Restricted share units (in shares)	327,820
Expected to vest, Weighted average fair value per unit (in dollars per share)	$ 3.70
The 2016 Equity Incentive Plan [Member] | Director [Member]
Non-vested, Restricted share units (in shares)	54,348
Non-vested, Weighted average fair value per unit (in dollars per share)	$ 4.31
Granted, Restricted share units (in shares)	95,999	54,348
Granted, Weighted average fair value per unit (in dollars per share)	$ 3.65
Non-vested, Restricted share units (in shares)	95,999	54,348
Non-vested, Weighted average fair value per unit (in dollars per share)	$ 3.70	$ 4.31
Expected to vest, Restricted share units (in shares)	95,999
Expected to vest, Weighted average fair value per unit (in dollars per share)	$ 3.70
Converted, Restricted share units (in shares)	(54,348)
Converted, Weighted average fair value per unit (in dollars per share)	$ 3.86
RSU Plan [Member]
Non-vested, Restricted share units (in shares)	27,271
Non-vested, Weighted average fair value per unit (in dollars per share)	$ 4.31
Non-vested, Restricted share units (in shares)		27,271
Non-vested, Weighted average fair value per unit (in dollars per share)		$ 4.31
Expected to vest, Restricted share units (in shares)
Expected to vest, Weighted average fair value per unit (in dollars per share)
Converted, Restricted share units (in shares)	(27,271)		(16,308)
Converted, Weighted average fair value per unit (in dollars per share)	$ 3.87	$ 18.36	$ 22.75

Note 7 - Share-based Compensa54

Note 7 - Share-based Compensation - Shares Issued Under the ESPP (Details) - Employee Stock Purchase Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares issued (in shares)	65,437	19,161	11,253
Price 1 [Member]
Purchase prices (in dollars per share)	$ 2.81
Shares issued (in shares)	65,437
Price 2 [Member]
Purchase prices (in dollars per share)	$ 4.45
Shares issued (in shares)		10,900
Price 3 [Member]
Purchase prices (in dollars per share)	$ 5.10
Shares issued (in shares)		8,261
Price 4 [Member]
Purchase prices (in dollars per share)	$ 8.94
Shares issued (in shares)			4,698
Price 5 [Member]
Purchase prices (in dollars per share)	$ 9.72
Shares issued (in shares)			1,899
Price 6 [Member]
Purchase prices (in dollars per share)	$ 11.10
Shares issued (in shares)			4,656

Note 8 - Collaborative and Li55

Note 8 - Collaborative and License Agreements (Details Textual) - USD ($)	May 05, 2016	Dec. 11, 2014	Apr. 30, 2014	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Development Expense					$ 43,980,000	$ 27,467,000	$ 23,468,000
Impairment of Intangible Assets (Excluding Goodwill)						19,738,000
Income Tax Expense (Benefit)				$ (6,900,000)		(6,908,000)
Reversal of Time Based Milestone						$ 1,500,000
Array BioPharma Inc [Member] | Collaborative Arrangement, Co-promotion [Member]
Expiration Period Following First Commercial on a Country by Country Basis		10 years
License Agreement Termination Notice Period		180 days
Array BioPharma Inc [Member] | Collaborative Arrangement, Co-promotion [Member] | Upfront Payment [Member]
Research and Development Expense		$ 20,000,000
STC. UNM. [Member]
Termination and License Fee	$ 325,000
Sentinel Oncology Limited [Member]
Contingent Payable			$ 90,000,000
Sentinel Oncology Limited [Member] | Initiation of GLP Toxicology Studies [Member]
Contingent Payable			$ 1,000,000

Note 9 - Net Investment and O56

Note 9 - Net Investment and Other Income (Expense) - Investments and Other Income (Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Investment income, net	$ 1,065	$ 240	$ 73
Net foreign exchange gain (loss)	(5)	1	(5)
Gain (loss) on sale of equipment	170	(69)	7
Gain on sale of investment
Impairment expense	(75)
Other income		50	5
Total investment and other income, net	$ 1,155	$ 222	$ 80

Note 10 - Income Tax (Details T

Note 10 - Income Tax (Details Textual) - USD ($)	Dec. 22, 2017	Jun. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Expense (Benefit)		$ (6,900,000)			$ (6,908,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				35.00%	35.00%	35.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ 50,100,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount				$ 27,200,000	$ 17,000,000
Operating Loss Carryforwards				317,100,000	260,000,000
Research and Development Expense				43,980,000	27,467,000	$ 23,468,000
Accounting Standards Update 2016-09 [Member]
Operating Loss Carryforward, Increase (Decrease) from New Accounting Pronouncements				5,000
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards				5,200,000	4,800,000
Unused Tax Credit Carryforward				16,200,000	15,200,000
Research and Development Expense				$ 109,100,000	102,100,000
Foreign Tax Authority [Member] | Canada Revenue Agency [Member] | Earliest Tax Year [Member]
Open Tax Year				2,008
Foreign Tax Authority [Member] | Australian Taxation Office [Member]
Operating Loss Carryforwards				$ 200,000
State and Local Jurisdiction [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards				3,400,000	3,100,000
Research and Development Expense				$ 47,800,000	44,700,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]
Open Tax Year				1,998
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount				$ 700,000
Capital Loss Carryforward [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Capital Loss Carry Forwards				150,200,000	140,600,000
Capital Loss Carryforward [Member] | State and Local Jurisdiction [Member] | Canada Revenue Agency [Member]
Capital Loss Carry Forwards				$ 150,300,000	$ 140,700,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Effective Income Tax Rate Reconciliation, Foreign Rate on Tangible Assets, Percent			10.50%

Note 10 - Income Tax - Componen

Note 10 - Income Tax - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current income tax expense (benefit)
Deferred income tax expense (benefit)			(6,908)
Total income tax expense (benefit)	$ (6,900)		$ (6,908)

Note 10 - Income Tax - Benefit

Note 10 - Income Tax - Benefit (Provision) for Income Taxes Applying the Statutory Federal Income Tax (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Tax benefit at statutory rate	35.00%	35.00%	35.00%
Change in fair value of warrant liability	0.00%	0.00%	0.10%
Stock based compensation	(1.60%)	(0.90%)	0.80%
Other	0.00%	0.40%	0.40%
Tax law changes	(88.10%)	0.00%	0.00%
Change in valuation allowance	54.70%	(23.70%)	(40.00%)
Net operating loss expiration and true ups	0.00%	0.00%	3.70%
Income tax benefit (provision)	0.00%	10.80%	0.00%

Note 10 - Income Tax - Net Defe

Note 10 - Income Tax - Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets
Accrued expenses and other	$ 623	$ 1,510
Tax benefits from losses carried forward and tax credits	126,552	147,001
Stock based compensation	2,547	4,119
Intangible assets	5,312	9,776
Other	242	207
Total deferred tax assets	135,276	162,613
Valuation allowance	(135,180)	(162,414)
Net deferred tax assets	96	199
Deferred tax liabilities
Prepaid expenses	96	199
Intangible asset
Total deferred tax liabilities	96	199
Net deferred tax liability	$ 0	$ 0

Note 10 - Income Tax - Uncertai

Note 10 - Income Tax - Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 662	$ 662	$ 545
Increase related to prior year tax positions			117
Decrease related to current year tax positions
Lapses of statute of limitations
Balance	$ 662	$ 662	$ 662

Note 11 - Contingencies, Comm62

Note 11 - Contingencies, Commitments, and Guarantees (Details Textual)	Nov. 30, 2016USD ($)ft²	Jan. 31, 2017USD ($)	Dec. 31, 2022USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 04, 2017ft²	May 31, 2008ft²
Employee-related Liabilities					$ 0
Deferred Compensation Arrangement with Individual, Contributions by Employer					300,000	$ 200,000	$ 200,000
Operating Leases, Rent Expense, Net					500,000	500,000	$ 500,000
Rental Payment, Monthly	$ 47,715
Scenario, Forecast [Member]
Rental Payment, Monthly				$ 57,910
Leased Office, Seattle Washington [Member]
Area of Leased Property | ft²								44,050
Leased Office, Seattle Washington [Member] | Scenario, Forecast [Member]
Rental Payment, Monthly			$ 124,808	$ 110,125
Headquarter Office and Laboratory Space [Member]
Area of Leased Property | ft²									17,000
Area of Real Estate Property, Additional Space | ft²	2,600
Retention Plan [Member]
Payments Related To Retention Payment Plan		$ 2,500,000
Other Labor-related Expenses					$ 100,000	$ 2,300,000

Note 11 - Contingencies, Comm63

Note 11 - Contingencies, Commitments, and Guarantees - Minimum Payments, Operating Lease (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 849
2,019	1,368
2,020	1,410
2,021	1,454
2,022	499
Thereafter
Total	$ 5,580

Note 12 - Related Party Trans64

Note 12 - Related Party Transactions (Details Textual)	Jan. 27, 2017USD ($)$ / shares$ / itemshares	Jun. 28, 2016USD ($)$ / shares$ / itemshares	Feb. 18, 2015USD ($)	Feb. 11, 2015USD ($)$ / sharesshares	Nov. 30, 2017USD ($)	Aug. 30, 2016USD ($)	Dec. 31, 2017USD ($)$ / sharesshares		Dec. 31, 2016USD ($)shares		Dec. 31, 2015USD ($)shares
Stock Issued During Period, Shares, New Issues | shares				2,250,000
Share Price | $ / shares				$ 9			$ 3.70
Proceeds from Issuance of Common Stock, Gross		$ 46,000,000	$ 24,000,000	$ 20,300,000
Proceeds from Contributed Capital							$ 300,000		$ 225,000
Short-swing Profit [Member]
Proceeds from Contributed Capital					$ 300,000	$ 200,000
Series E Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues | shares	1,818
Preferred Stock Permitted to Issue Shares | shares	1,818
Convertible Preferred Stock Price Per Share | $ / item	3,300
Proceeds from Issuance of Convertible Preferred Stock, Gross	$ 6,000,000
Series E Convertible Preferred Stock [Member] | New Enterprise Associates [Member]
Preferred Stock Permitted to Issue Shares | shares	1,818
Proceeds from Issuance of Convertible Preferred Stock, Gross	$ 6,000,000
Series D Convertible Preferred Stock [Member]
Preferred Stock Permitted to Issue Shares | shares		17,250
Convertible Preferred Stock Price Per Share | $ / item		800
Proceeds from Issuance of Convertible Preferred Stock, Gross		$ 13,800,000
Series D Convertible Preferred Stock [Member] | BVF, Inc [Member]
Stock Issued During Period, Shares, New Issues | shares		17,250
Proceeds from Issuance of Convertible Preferred Stock, Gross		$ 13,800,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues | shares	26,659,300	6,708,333					26,659,300	[1]	6,708,333	[1]	2,449,943	[1]
Share Price | $ / shares	$ 3.30	$ 4.80
Proceeds from Issuance of Common Stock, Gross	$ 88,000,000	$ 32,200,000
Common Stock [Member] | New Enterprise Associates [Member]
Percentage of Common Stock Owned by Related Party	5.00%
Common Stock [Member] | BVF, Inc [Member]
Percentage of Common Stock Owned by Related Party		5.00%
[1]	Common stock shares for the years ended December 31, 2015 and 2014 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Seattle Genetics, Inc. and Valley Acquistion Sub, Inc. [Member] - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	Jan. 31, 2018	Jan. 30, 2018
Business Acquisition, Share Price	$ 10	$ 10
Business Combination, Consideration Transferred	$ 614

Note 14 - Condensed Quarterly66

Note 14 - Condensed Quarterly Financial Data (Unaudited) (Details Textual)	Nov. 29, 2016	Nov. 18, 2016	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Impairment of Intangible Assets (Excluding Goodwill)							$ 19,738,000
Reversal of Time Based Milestone							1,500,000
Income Tax Expense (Benefit)				$ (6,900,000)			$ (6,908,000)
Series D Convertible Preferred Stock [Member]
Accretion on Beneficial Conversion Feature Associated with Convertible Preferred Stock			$ 1,000,000	1,600,000
Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6	6				6	6
In Process for Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill)							$ 19,700,000
Operating Expense [Member]
Severance Costs					$ 1,600,000
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost					$ 2,300,000
Operating Expense [Member] | STC. UNM. [Member]
Reversal of Time Based Milestone				1,500,000
Operating Expense [Member] | STC. UNM. [Member] | In Process for Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill)				$ 19,700,000

Note 14 - Condensed Quarterly67

Note 14 - Condensed Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Operating expenses (1)

$ 17,148

[1]

$ 14,358

[1]

$ 15,021

[1]

$ 11,562

[1]

$ 10,590

[1]

$ 10,792

[1]

$ 30,483

[1]

$ 12,970

[1]

$ 58,089

$ 64,835

$ 32,789

Net loss

$ (16,762)

[2]

$ (14,061)

[2]

$ (14,709)

[2]

$ (12,384)

[2]

$ (10,512)

[2]

$ (11,762)

[2]

$ (25,132)

[2]

$ (12,887)

[2]

$ (56,934)

$ (57,705)

$ (32,581)

Net loss per share basic and diluted (in dollars per share)

$ (0.33)

[3]

$ (0.28)

[3]

$ (0.30)

[3]

$ (0.30)

[3]

$ (0.47)

[3]

$ (0.52)

[3]

$ (1.57)

[3]

$ (0.81)

[3]

$ (1.21)

[4]

$ (3.13)

[4]

$ (2.02)

[4]

[1]

Operating expenses for the three months ended March 31, 2016 includes a cash severance and insurance benefits of $1.6 million and non-cash compensation expense of $2.3 million due to the acceleration of share-based compensation related to changes in management in January 2016. Operating expenses for the three months ended June 30, 2016 includes an intangible asset impairment charge of $19.7 million in connection with our termination of the STC.UNM license agreement and a $1.5 million reversal of the previously recorded time-based milestones for license fees in connection with the termination of the STC.UNM license agreement (see Note 8).

[2]

Net loss attributable to common stockholders for the three months ended June 30, 2016 included an income tax benefit of $6.9 million due to the reversal of its deferred tax liability, which related solely to the impairment of the indefinite-lived intangible asset (see Note 8), and a $1.6 million deemed dividend related to the beneficial conversion feature on our Series D convertible preferred stock. Net loss attributable to common stockholders for the three months ended September 30, 2016 included a $1.0 million deemed dividend.

[3]

Basic and diluted net loss per share for all periods presented have been adjusted retroactively to reflect the 1-for-6 reverse stock split.

[4]

Basic and diluted net loss per share, and shares to used compute basic and diluted net loss per share for the year ended December 31, 2015 have been adjusted retroactively to reflect the 1-for-6 reverse stock split.